<SEC-DOCUMENT>0001157523-20-001422.txt : 20201103
<SEC-HEADER>0001157523-20-001422.hdr.sgml : 20201103
<ACCEPTANCE-DATETIME>20201103073236
ACCESSION NUMBER:		0001157523-20-001422
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20201102
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201103
DATE AS OF CHANGE:		20201103

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		201281914

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a52318785.htm
<DESCRIPTION>MOLINA HEALTHCARE, INC. 8-K
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:moh="http://molinahealthcare.com/20201102" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html" />
</head>

<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_e4854e4176cc4795843bdebcc4cbe14f" contextRef="c20201102to20201102" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_7ae851094a934914bcf85dd04117b349" contextRef="c20201102to20201102">0001179929</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="moh-20201102.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20201102to20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-02</xbrli:startDate><xbrli:endDate>2020-11-02</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>

  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">UNITED STATES</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">______________</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_d8cb1846f79f49f6b29db51b424463c4" contextRef="c20201102to20201102">8-K</ix:nonNumeric></div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">______________</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Current Report</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Date of Report (Date of earliest event reported): November 3, 2020 (<ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_ee9293229f2240309a8ff96e5eefb42d" contextRef="c20201102to20201102" format="ixt:datemonthdayyearen">November 2, 2020</ix:nonNumeric>)</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">______________</div>

    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_5fce183580c84d2681f9e32b777bba3c" contextRef="c20201102to20201102">MOLINA HEALTHCARE, INC.</ix:nonNumeric><br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Exact name of registrant as specified in its charter)</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <table cellspacing="0" cellpadding="0" id="z4dcfc7061685462c9a643dcc4de4c53d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 32.81%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_fec0da96a2da44ad86783bd6f33141b6" contextRef="c20201102to20201102" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 34.18%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_0e218934daa7442285ff4eb4169c3b23" contextRef="c20201102to20201102">001-31719</ix:nonNumeric><br />
            </div>
          </td>

    <td style="width: 33.01%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_53de4d2dd0fb467ea031450800b4f30f" contextRef="c20201102to20201102">13-4204626</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 32.81%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(State or other jurisdiction of </div>
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">incorporation)</div>
          </td>

    <td style="width: 34.18%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Commission File Number)</div>
          </td>

    <td style="width: 33.01%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div>&#160;</div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">______________</div>

    <div>&#160;</div>

    <table cellspacing="0" cellpadding="0" id="zc8807758e4394d398b39a3947b4b0fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_b32e977aebaa40d6b4bcc1a1c577996e" contextRef="c20201102to20201102">200 Oceangate, Suite 100</ix:nonNumeric>,
              <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_3057238918424d12aff800096e7d679d" contextRef="c20201102to20201102">Long Beach</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_04d834502b3946c3b688edfa13f62e58" contextRef="c20201102to20201102" format="ixt-sec:stateprovnameen">California</ix:nonNumeric>
              <ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_29670d01a13a47899c9429aa69fb33a7" contextRef="c20201102to20201102">90802</ix:nonNumeric></div>
          </td>

  </tr>

  <tr>

    <td style="width: 100%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Address of principal executive offices)</div>
          </td>

  </tr>


</table>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
    </div>

    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric name="dei:CityAreaCode" id="Fact_2d1353d12f6644b4ba92b3cb9ac1bc23" contextRef="c20201102to20201102">562</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_171c109229a6401aa3d49465df6e7ee3" contextRef="c20201102to20201102">435-3666</ix:nonNumeric></div>

    <div>&#160;</div>

    <div>&#160;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</div>

    <div>&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_e2934592738845ae85483090ff6fa4f7" contextRef="c20201102to20201102" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric> Written communications pursuant to Rule 425
      under the Securities Act (17 CFR 230.425)</div>

    <div>&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_a1de93c62a724233956ffea0b70df45c" contextRef="c20201102to20201102" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; Soliciting material pursuant to Rule 14a-12
      under the Exchange Act (17 CFR 240.14a-12)</div>

    <div>&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_ab963e3bd8c642da80bb8f4d1af6ea42" contextRef="c20201102to20201102" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; Pre-commencement communications pursuant to
      Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>

    <div>&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_0b573b26bbcb4679854ba3da29919bfd" contextRef="c20201102to20201102" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric>&#160; Pre-commencement communications pursuant to
      Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>

    <div>&#160;</div>

    <div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    </div>

    <div> <br />
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 37.55%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</div>
            </td>

    <td style="width: 20.47%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading Symbol(s)</div>
            </td>

    <td style="width: 41.98%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</div>
            </td>

  </tr>

  <tr>

    <td style="width: 37.55%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_2fa51f2167654174a37741aaf1559ea0" contextRef="c20201102to20201102">Common Stock, $0.001 Par Value</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 20.47%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_be72255bb4ab4e73a1bcd9e4b8e74767" contextRef="c20201102to20201102">MOH</ix:nonNumeric><br />
              </div>
            </td>

    <td style="width: 41.98%; vertical-align: top; border-left: #000000 2px solid; border-right: #000000 2px solid; border-top: #000000 2px solid; border-bottom: #000000 2px solid;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_479476c1029e405c991bd60482260061" contextRef="c20201102to20201102" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric><br />
              </div>
            </td>

  </tr>


</table>
    </div>

    <div>&#160;</div>

    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or
      Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <table cellspacing="0" cellpadding="0" id="z89a1a1b416fe45cbb664fcec7450c81d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 97.46%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging growth company</div>
          </td>

    <td style="width: 2.54%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_0a6beb63c12445c2927975a7c3ebfd0b" contextRef="c20201102to20201102" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric><br />
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 97.46%; vertical-align: bottom;" rowspan="1">&#160;</td>

    <td style="width: 2.54%; vertical-align: bottom;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 97.46%; vertical-align: bottom;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
              new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.</div>
          </td>

    <td style="width: 2.54%; vertical-align: bottom;">
            <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9744;</div>
          </td>

  </tr>


</table>
    <div> <br />
    </div>

    <div> <br />
    </div>

    <div> <br />
    </div>

    <div> <br />
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;" /></div>

    </div>

    &#160;
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zc8ee855d1208464e9149022fe5fca593">


  <tr>

    <td style="width: 9%;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 1.01.</span></td>

    <td style="width: 91%;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entry into a Material Definitive Agreement.</span></td>

  </tr>


</table>
      </div>

      <div> <br />
      </div>

      <div> <br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">On November 2, 2020, Molina Healthcare, Inc., a Delaware
          corporation (the &#8220;Company&#8221;), entered into a purchase agreement (the &#8220;Purchase Agreement&#8221;), by and between the Company and BofA Securities, Inc., acting as representative of the several initial purchasers named in Schedule A thereto (the &#8220;Initial
          Purchasers&#8221;), relating to the issuance and sale of $650 million aggregate principal amount of the Company&#8217;s senior notes due 2030 (the &#8220;Notes&#8221;), </span>in a private offering to individuals reasonably believed to be &#8220;qualified institutional
        buyers&#8221; pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and to certain persons outside the United States in reliance on Regulation S under the Securities Act.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160; The offering is expected to close on or about November 17, 2020, subject to the satisfaction of customary closing conditions (the &#8220;Settlement Date&#8221;).</span></div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Notes will bear interest at a rate of 3.875% per year.&#160; Interest will be payable semi-annually in arrears on <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">May 15</span> and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">November 15</span> of each year, commencing <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">May 15</span>, 2021, and will accrue from the Settlement Date.&#160; The Notes will mature on November 15, 2030.</div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company estimates that after deducting fees and expenses payable by the Company, the net proceeds from the issuance and sale of the
        Notes will be approximately $641 million (the &#8220;Net Proceeds&#8221;). The Company intends to use approximately $346 million of the Net Proceeds to redeem the entire $330 million outstanding principal amount of its 4.875% senior notes due 2025, and to pay
        related fees and expenses.&#160; The Company intends to use the remaining Net Proceeds for general corporate purposes, which may include repayment of indebtedness, share repurchases, funding for acquisitions, capital expenditures, additions to working
        capital and capital contributions to the Company&#8217;s health plan subsidiaries to meet statutory requirements in new or existing states.</div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Purchase Agreement contains customary representations, warranties and agreements by the Company.&#160; In addition, the Company has agreed
        to indemnify the Initial Purchasers against certain liabilities, as more particularly described in Section 7(a) of the Purchase Agreement.</div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing summary of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the
        full text of the Purchase Agreement. A copy of the Purchase Agreement is being filed as Exhibit 1.1 hereto and is incorporated herein by reference.</div>

      <div><br />
      </div>

      <div><br />
      </div>

      <div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 9%;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 8.01.</span></td>

    <td style="width: 91%;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Other Events.</span></td>

  </tr>


</table>
        </div>

        <div>&#160;</div>

      </div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On November 2, 2020, the Company issued a press release announcing the pricing of the Notes.&#160; A copy of the press release is being filed
        as Exhibit 99.1 to this Current Report on Form 8-K.</div>

      <div><br />
      </div>

      <div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">


  <tr>

    <td style="width: 9%; font-weight: bold;">Item 9.01.</td>

    <td style="width: 91%; font-weight: bold;">Financial Statements and Exhibits.</td>

  </tr>


</table>
        </div>

      </div>

      <div><br />
      </div>

      <div style="text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</span><span style="text-indent: 0px; font-size: 5.14pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Exhibits:</span></div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z6bd15c2f810849ffa509e6cf80359ec2">


  <tr>

    <td style="width: 9%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> Exhibit</div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">No.</div>
            </td>

    <td style="width: 91%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"> <br />
              </div>
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 91%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="a52318785ex1_1.htm">1.1</a></div>
            </td>

    <td style="width: 91%; vertical-align: top;">
              <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><a href="a52318785ex1_1.htm">Purchase
                    Agreement, dated November 2, 2020, by and among the Company and BofA Securities, Inc., as representative of the several initial purchasers named in Schedule A thereto</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br />
                  </span></span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 91%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="a52318785ex99_1.htm">99.1</a></div>
            </td>

    <td style="width: 91%; vertical-align: top;">
              <div style="text-align: left;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><a href="a52318785ex99_1.htm">Press
                    release of Molina Healthcare, Inc. issued November 2, 2020</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br />
                  </span></span></div>
            </td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 91%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 9%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div>
            </td>

    <td style="width: 91%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover page information from Molina Healthcare, Inc.&#8217;s Current Report on Form 8-K filed on November 3, 2020 formatted in iXBRL (Inline Extensible
                Business Reporting Language)</div>
            </td>

  </tr>


</table>
      <div style="text-align: center;"><br />
      </div>

      <div>&#160;</div>

      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURE</div>

      <div>&#160;</div>

      <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
        behalf by the undersigned hereunto duly authorized.</div>

      <div><br />
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z515111d10cbd4d3e9f49cc58674546f8">


  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td colspan="2" style="vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MOLINA HEALTHCARE, INC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Date: November 3</span>, 2020</div>
            </td>

    <td style="width: 4%; vertical-align: bottom;">
              <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div>
            </td>

    <td style="width: 46%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Jeff D. Barlow</div>
            </td>

  </tr>

  <tr>

    <td style="width: 50%; vertical-align: bottom;">&#160;</td>

    <td style="width: 4%; vertical-align: bottom;">&#160;</td>

    <td style="width: 46%; vertical-align: bottom;">
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Jeff D. Barlow,</div>
              <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Legal Officer and Secretary</div>
            </td>

  </tr>


</table>
      <div> <br />
      </div>

      <div> <br />
      </div>

      <div style="text-align: center;"> - 2 -<br />
      </div>

      <div> </div>

    </div>

  </div>

</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>a52318785ex1_1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 1.1</font><br>
  </div>
  <div><br>
  </div>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: small-caps; font-weight: bold;">PURCHASE AGREEMENT</div>
    <div>&#160;</div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 2, 2020</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-variant: small-caps;">BofA Securities, Inc.</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>&#160;&#160;&#160;&#160;&#160;As Representative of the Initial Purchasers</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c/o BofA Securities, Inc.<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>One Bryant Park<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>New York, New York 10036</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Molina Healthcare, Inc., a Delaware corporation (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company</font>&#8221;), proposes to issue and sell to BofA Securities, Inc.&#160; (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">BofAS</font>&#8221;) and the other several Initial Purchasers
      named in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font> attached hereto (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Initial

        Purchasers</font>&#8221;), acting severally and not jointly, the respective amounts set forth in such <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font> of $650,000,000 aggregate principal amount of the
      Company&#8217;s 3.875% Senior Notes due 2030 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Notes</font>&#8221;). The Notes will be issued pursuant to an indenture, to be dated as of Closing Date (as defined
      below) (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indenture</font>&#8221;), between the Company and U.S. Bank National Association, as trustee (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Trustee</font>&#8221;). BofAS has agreed to act as the representative of the several Initial Purchasers (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Representative</font>&#8221;) in connection with the offering and sale of the Notes.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company intends to use the net proceeds from the issuance and sale of the Notes to redeem the entire $330 million outstanding principal
      amount of 4.875% senior notes due 2025 and to pay related fees and expenses.&#160; The Company intends to use the remaining net proceeds of this offering for general corporate purposes, which may include repayment of indebtedness, share repurchases,
      funding for acquisitions, capital expenditures, additions to working capital and capital contributions to the Issuer&#8217;s health plan subsidiaries to meet statutory requirements in new or existing states.&#160; The issuance and sale of the Notes and the use
      of the net proceeds from the issuance and sale of the Notes as more fully described in the Pricing Disclosure Package (as defined below) and the Final Offering Memorandum (as defined below) and the payment of transaction costs are referred to herein,
      collectively, as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Transactions</font>.&#8221; This Purchase Agreement (this &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Agreement</font>&#8221;), the Notes and the Indenture are referred to herein as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Transaction Documents</font>.&#8221;</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Notes are to be offered and sold to or through the Initial Purchasers without being registered with the Securities and Exchange
      Commission (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Commission</font>&#8221;) under the Securities Act of 1933 (as amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Securities Act</font>,&#8221; which term, as used herein, includes the rules and regulations of the Commission promulgated thereunder), in reliance upon exemptions therefrom. Pursuant to the terms of the Notes and the
      Indenture, investors who acquire the Notes shall be deemed to have agreed that the Notes may only be resold or otherwise transferred, after the date hereof, if such Notes are registered for sale under the Securities Act or if an exemption from the
      registration requirements of the Securities Act is available (including the exemptions afforded by Rule 144A under the Securities Act (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Rule 144A</font>&#8221;)
      or Regulation S under the Securities Act (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Regulation S</font>&#8221;)). The Company agrees that the Initial Purchasers may resell, subject to the conditions
      set forth herein, all or a portion of the Notes to purchasers (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Subsequent Purchasers</font>&#8221;) on the terms set forth in the Pricing Disclosure
      Package.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with the sale of the Notes, the Company has prepared and delivered to each Initial Purchaser copies of a Preliminary Offering
      Memorandum, dated November 2, 2020 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Preliminary Offering Memorandum</font>&#8221;). Prior to the time when the sales of the Notes were first made (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Time of Sale</font>&#8221;), the Company has prepared and delivered to each Initial Purchaser a Pricing Supplement, dated November 2, 2020 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Pricing Supplement</font>&#8221;), describing the terms of the Notes, each for use by such Initial Purchaser in connection with its solicitation of offers to
      purchase the Notes. A copy of the Pricing Supplement is attached hereto as <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule B-1</u></font>.&#160; The Preliminary Offering Memorandum and the Pricing Supplement are
      herein referred to as the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Pricing Disclosure Package</font>.&#8221; Promptly after this Agreement is executed and delivered, the Company will prepare and
      deliver to each Initial Purchaser a final offering memorandum dated the date hereof (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Final Offering Memorandum</font>&#8221;).</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All references herein to the terms &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Pricing
        Disclosure Package</font>&#8221; and &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Final Offering Memorandum</font>&#8221; shall be deemed to mean and include all information filed under the Securities
      Exchange Act of 1934 (as amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Exchange Act</font>,&#8221; which term, as used herein, includes the rules and regulations of the Commission promulgated
      thereunder) prior to the Time of Sale and incorporated by reference in the Pricing Disclosure Package (including the Preliminary Offering Memorandum) or the Final Offering Memorandum (as the case may be), and all references herein to the terms &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">amend</font>,&#8221; &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">amendment</font>&#8221; or &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">supplement</font>&#8221; with respect to the Final Offering Memorandum shall be deemed to mean and include all information filed under the Exchange Act after the Time of Sale that
      are deemed to be incorporated by reference in the Final Offering Memorandum.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company hereby confirms its agreements with the Initial Purchasers as follows:</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 1.&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Purchase, Sale and Delivery
        of the Notes.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company agrees to issue and sell to the several Initial Purchasers, all of the Notes, and subject to the conditions set forth herein and on the basis of the representations, warranties, terms and
        agreements herein, the Initial Purchasers agree, severally and not jointly, to purchase from the Company the aggregate principal amount of the Notes set forth opposite their names on <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font>, at a purchase price of 98.75% of the principal amount thereof payable on the Closing Date.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">One or more certificates for the Notes in definitive form to be purchased by the Initial Purchasers shall be delivered to, and payment therefor shall be made at, the offices of Latham &amp; Watkins LLP
        (or such other place as may be agreed to by the Company and BofAS) at 9:00 a.m. New York City time, on November 17, 2020, or such other time and date as BofAS shall designate by notice to the Company (the time and date of such closing are called
        the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Closing Date</font>&#8221;). The Company hereby acknowledges that circumstances under which BofAS may provide notice to postpone the Closing Date as
        originally scheduled include, but are in no way limited to, any determination by the Company or the Initial Purchasers to recirculate to investors copies of an amended or supplemented Offering Memorandum or a delay as contemplated by the provisions
        of Section&#160;15 hereof.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">2</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company shall deliver, or cause to be delivered, to BofAS for the accounts of the several Initial Purchasers certificates for the Notes at the Closing Date against the irrevocable release of a wire
        transfer of immediately available funds for the amount of the purchase price therefor. The certificates for the Notes shall be in such denominations and registered in the name of Cede&#160;&amp; Co., as nominee of The Depository Trust Company (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Depositary</font>&#8221;), and shall be made available for inspection on the business day preceding the Closing Date at a location in New York City, as BofAS may
        designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the Initial Purchasers.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Each Initial Purchaser severally and not jointly represents and warrants to, and agrees with, the Company that:</font></div>
    <div>&#160;</div>
    <div style="margin-left: 36pt; text-indent: 27pt;"> (i)&#160;&#160;&#160;&#160;&#160;&#160; it will solicit offers for the Notes only (a) from, and will offer such Notes only to, persons who it reasonably believes are &#8220;qualified institutional buyers&#8221; within the meaning of Rule 144A
      (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Qualified Institutional Buyers</font>&#8221;) in transactions meeting the requirements of Rule 144A or (b)&#160;upon the terms and conditions set forth in <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif;"><u>Annex I</u></font> to this Agreement;</div>
    <div> <br>
    </div>
    <div style="text-indent: 27pt; margin-left: 36pt;">(ii)&#160;&#160;&#160;&#160;&#160; it is an institutional &#8220;accredited investor&#8221; within the meaning of Rule 501(a)(1), (2), (3)&#160;or (7)&#160;under the Securities Act; and</div>
    <div> <br>
    </div>
    <div style="margin-left: 36pt; text-indent: 27pt;">(iii)&#160;&#160;&#160;&#160; it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer to sell the Notes in any manner involving a public offering within the meaning of
      Section&#160;4(a)(2) of the Securities Act.</div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 2.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Representations and Warranties of the Company</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The Company hereby represents,
        warrants and covenants to each Initial Purchaser that, as of the date hereof and as of the Closing Date (references in this Section&#160;2 to the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offering
          Memorandum</font>&#8221; are to (x)&#160;the Pricing Disclosure Package in the case of representations and warranties made as of the date hereof and (y)&#160;the Final Offering Memorandum in the case of representations and warranties made as of the Closing
        Date):</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Pricing Disclosure Package and Offering Memorandum.</font> Neither the Pricing Disclosure Package, as
        of the Time of Sale, nor the Final Offering Memorandum, as of its date or (as amended or supplemented in accordance with Section&#160;3(b) hereof, as applicable) as of the Closing Date, contains any untrue statement of a material fact or omits to state
        a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>
        that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by such Initial
        Purchaser through the Representative expressly for use in the Pricing Disclosure Package, the Final Offering Memorandum or amendment or supplement thereto, as the case may be, it being understood and agreed that such information furnished by or on
        behalf of any Initial Purchaser consists only of the information described as such in Section&#160;7(b) hereof.&#160; The Company has not distributed and will not distribute, prior to the later of the Closing Date and the completion of the Initial
        Purchasers&#8217; distribution of the Notes, any offering material in connection with the offering and sale of the Notes other than the Pricing Disclosure Package and the Final Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">3</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Registration Required.</font> Assuming the accuracy of the representations and warranties of the
        Initial Purchasers set forth in Section&#160;1(d) hereof and compliance by the Initial Purchasers with the procedures set forth in Section&#160;5 hereof, it is not necessary in connection with the offer, sale and delivery of the Notes to the Initial
        Purchasers and to each Subsequent Purchaser in the manner contemplated by this Agreement and the Offering Memorandum to register the Notes under the Securities Act or to qualify the Indenture under the Trust Indenture Act of 1939 (as amended, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Trust Indenture Act</font>,&#8221; which term, as used herein, includes the rules and regulations of the Commission promulgated thereunder).</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Eligibility for Resale Under Rule 144A.</font> The Notes are eligible for resale pursuant to Rule 144A
        and will not be, at the Closing Date, of the same class as securities listed on a national securities exchange registered under Section&#160;6 of the Exchange Act or quoted in a U.S. automated interdealer quotation system.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Integration of Offerings.</font> None of the Company, its affiliates (as defined in Rule 501 under the
        Securities Act) (each, an &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Affiliate</font>&#8221;), or any person acting on its or any of their behalf (other than the Initial Purchasers, as to whom the
        Company makes no representation or warranty) has, directly or indirectly, solicited any offer to buy or offered to sell, or will, directly or indirectly, solicit any offer to buy or offer to sell, in the United States or to any United States
        citizen or resident, any security which is or would be integrated with the sale of the Notes in a manner that would require the Notes to be registered under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No General Solicitation.</font> None of the Company, its Affiliates, or any person acting on its or any
        of their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has engaged or will engage, in connection with the offering of the Notes, in any form of general solicitation or general advertising
        within the meaning of Rule 502 under the Securities Act other than by means of a Permitted General Solicitation (as defined below). With respect to those Notes sold in reliance upon Regulation S, (i)&#160;none of the Company, its Affiliates or any
        person acting on its or their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has engaged or will engage in any directed selling efforts within the meaning of Regulation S and (ii)&#160;each of the
        Company and its Affiliates and any person acting on its or their behalf (other than the Initial Purchasers, as to whom the Company makes no representation or warranty) has complied with and will comply with the offering restrictions set forth in
        Regulation S.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">4</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company Additional Written Communications; Permitted General Solicitations.</font> The Company has not
        prepared, made, used, authorized, approved or distributed and will not prepare, make, use, authorize, approve or distribute (x)&#160;any written communication that constitutes an offer to sell or a solicitation of an offer to buy the Notes other than
        (i)&#160;the Pricing Disclosure Package, (ii)&#160;the Final Offering Memorandum and (iii)&#160;any electronic road show or other written communications, other than any Permitted General Solicitation, in each case used in accordance with Section&#160;3(b) hereof or
        (y)&#160;any general solicitation other than any such solicitation (i)&#160;listed on <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule B-2</u></font> hereto or (ii) in accordance with Section&#160;3(j) hereof (each such
        solicitation referred to in clause (y)(i)&#160;and (y)(ii), a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Permitted General Solicitation</font>&#8221;). Each such communication or Permitted General
        Solicitation by the Company or its agents and representatives (other than the Initial Purchasers, in their capacity as such) pursuant to clause (x)(iii)&#160;of the preceding sentence (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Company Additional Written Communication</font>&#8221;), when taken together with the Pricing Disclosure Package, did not as of the Time of Sale, and at the Closing Date will not, contain any untrue statement
        of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font> that this representation, warranty and agreement shall not apply to statements in or omissions from each such Company Additional Written Communication made in reliance upon and in conformity with information
        furnished to the Company in writing by any Initial Purchaser through the Representative expressly for use in any Company Additional Written Communication.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Incorporated Documents.</font> The documents incorporated or deemed to be incorporated by reference in
        the Offering Memorandum at the time they were or hereafter are filed with the Commission (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Incorporated Documents</font>&#8221;) complied
        and will comply in all material respects with the requirements of the Exchange Act. Each such Incorporated Document, when taken together with the Pricing Disclosure Package, did not as of the Time of Sale, and at the Closing Date will not, contain
        any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Purchase Agreement.</font> This Agreement has been duly authorized, executed and delivered by the
        Company.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Indenture.</font> The Indenture has been duly authorized by the Company and, at the Closing Date,
        will have been duly executed and delivered by the Company and will constitute a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by
        bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(j)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Notes.</font> The Notes to be purchased by the Initial Purchasers from the Company will on the
        Closing Date be in the form contemplated by the Indenture, have been duly authorized for issuance and sale pursuant to this Agreement and the Indenture and, at the Closing Date, will have been duly executed by the Company and, when authenticated in
        the manner provided for in the Indenture and delivered against payment of the purchase price therefor, will constitute valid and binding obligations of the Company, enforceable in accordance with their terms, except as the enforcement thereof may
        be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles, and will be entitled to the benefits of the Indenture.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">5</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(k)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Descriptions of the Transaction Documents.</font> Each Transaction Document conforms in all material
        respects to the description thereof contained in the Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(l)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Material Adverse Change.</font> Since the date of the most recent financial statements of the Company
        included or incorporated in the Offering Memorandum (exclusive of any amendment or supplement thereto), (i)&#160;there has not been any change in the capital stock, long-term debt, notes payable or current portion of long-term debt of the Company or any
        of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material adverse
        change, in or affecting the business, properties, management, financial position, stockholders&#8217; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole; (ii)&#160;neither the Company nor any of its subsidiaries
        has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a
        whole, except as otherwise disclosed in the Offering Memorandum (exclusive of any amendment or supplement thereto); and (iii)&#160;neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from
        fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as
        otherwise disclosed in the Offering Memorandum (exclusive of any amendment or supplement thereto).</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(m)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Independent Accountants.</font> Ernst&#160;&amp; Young LLP, which has issued its opinion with respect to the
        audited financial statements (including the related notes thereto) incorporated by reference in the Offering Memorandum is an independent registered public accounting firm with respect to the Company and its subsidiaries within the meaning of the
        applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act and the Exchange Act.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(n)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Preparation of the Financial Statements.</font> The financial statements, together with the related
        schedules and notes, included or incorporated by reference in the Offering Memorandum present fairly the financial position of the Company and its consolidated subsidiaries at the dates indicated and the statement of operations, stockholders&#8217;
        equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; said financial statements have been prepared in conformity with generally accepted accounting principles as applied in the United States (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">GAAP</font>&#8221;) applied on a consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in accordance with GAAP the
        information required to be stated therein. The selected financial data and the summary financial information incorporated by reference in the Offering Memorandum present fairly the information shown therein and have been compiled on a basis
        consistent with that of the audited financial statements incorporated by reference therein. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Offering Memorandum fairly present the information called
        for in all material respects and have been prepared in accordance with the Commission&#8217;s rules and guidelines applicable thereto.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">6</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(o)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Incorporation and Good Standing.</font> The Company and each of its subsidiaries have been duly organized
        and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property
        or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be
        so duly organized, qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position, stockholders&#8217; equity, results
        of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under each of the Transaction Documents to which it is a party (a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Material Adverse Effect</font>&#8221;); other than the subsidiaries listed on Exhibit 21.1 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, the Company does not own
        or control, directly or indirectly, any corporation, association or other entity or 5% or more of the shares of capital stock or any other equity interest in any firm, partnership, joint venture, association or other entity.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(p)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Capitalization.</font> As of September 30, 2020, on a consolidated basis, after giving effect to the
        Transactions, the Company would have an authorized and outstanding capitalization as set forth in the section of the Offering Memorandum entitled &#8220;Capitalization&#8221;; all of the outstanding shares of capital stock, including the common stock (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Common Stock</font>&#8221;), of the Company have been duly authorized and validly issued and are fully paid and non-assessable, have been issued in compliance
        with all applicable securities laws and are not subject to any pre-emptive or similar rights; except as described in the Offering Memorandum, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options
        to acquire, or instruments convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind
        relating to the issuance of any capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; all the outstanding shares of capital stock or other equity interests of
        each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance,
        security interest, restriction on voting or any other claim of any third party.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(q)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Termination of Agreements.</font> Except as otherwise disclosed in the Offering Memorandum, neither
        the Company nor any subsidiary has sent or received any communication regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Offering Memorandum, and no such termination or non-renewal
        has been threatened by the Company or any subsidiary or, to the knowledge of the Company, any other party to any such contract or agreement, except in each such case for any termination or non-renewal that could not reasonably be expected,
        individually or in the aggregate, to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">7</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(r)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Material Actions or Proceedings.</font> Except as otherwise disclosed in the Offering Memorandum,
        there are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may
        be the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; except as otherwise disclosed in the Offering Memorandum, to
        the knowledge of the Company no such investigations, actions, suits or proceedings are threatened or contemplated by any governmental or regulatory authority.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(s)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Solvency.</font> The Company (on a consolidated basis together with its subsidiaries) is, and immediately
        after the Closing Date will be, Solvent. As used herein, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Solvent</font>&#8221; means, with respect to any person on a particular date, that on such
        date (i)&#160;the fair market value of the assets of such person is greater than the total amount of liabilities (including contingent liabilities) of such person, (ii)&#160;the present fair salable value of the assets of such person is greater than the
        amount that will be required to pay the probable liabilities of such person on its debts as they become absolute and matured, (iii)&#160;such person is able to realize upon its assets and pay its debts and other liabilities, including contingent
        obligations, as they mature and (iv)&#160;such person does not have unreasonably small capital.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(t)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Non-Contravention; No Authorizations or Approvals.</font> Neither the Company nor any of its subsidiaries
        is (i)&#160;in violation of its charter, bylaws or similar organizational document; (ii)&#160;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term,
        covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is
        bound (including, without limitation, the Company&#8217;s $1,000 million revolving credit facility, 5.375% notes due 2022, 4.875% notes due 2025 and 4.375% notes due 2028) or to which any of the property or assets of the Company or any of its
        subsidiaries is subject; or (iii)&#160;in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&#160;and (iii)&#160;above, for any such
        default or violation that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. The execution, delivery and performance of the Transaction Documents by the Company and the issuance and delivery of
        the Notes, and consummation of the transactions contemplated hereby and thereby and by the Offering Memorandum (including the Transactions) have been duly authorized by all necessary corporate or limited liability company action and will not
        (i)&#160;conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any
        of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement, note, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is
        bound (including, without limitation, the Company&#8217;s $1,000 million revolving credit facility, 5.375% notes due 2022, 4.875% notes due 2025 and 4.375% notes due 2028) or to which any of the property or assets of the Company or any of its
        subsidiaries is subject, (ii)&#160;result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its subsidiaries or (iii)&#160;result in the violation of any law or statute or any judgment,
        order, rule or regulation of any court or arbitrator or governmental or regulatory authority. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is
        required for the execution, delivery and performance of the Transaction Documents by the Company, or the issuance and delivery of the Notes, or consummation of the transactions contemplated hereby and thereby and by the Offering Memorandum, other
        than as have been obtained or made by the Company and are in full force and effect under the Securities Act, applicable securities laws of the several states of the United States or provinces of Canada.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">8</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(u)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Related Party Transactions.</font> No relationship, direct or indirect, exists between or among the
        Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be disclosed in a registration
        statement on Form S-1 which is not so disclosed in the Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(v)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Intellectual Property.</font> The Company and its subsidiaries own or possess adequate rights to use or
        can acquire on reasonable terms all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses and know-how (including trade secrets and other unpatented
        and/or unpatentable proprietary or confidential information, systems or procedures) (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Intellectual Property Rights</font>&#8221;) necessary for
        the conduct of their respective businesses; and the expected expiration of any of such Intellectual Property Rights would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any
        notice of any claim of infringement of or conflict with any such Intellectual Property Rights of others.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(w)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">All Necessary Permits, etc.</font> The Company and each subsidiary possess all licenses, certificates,
        permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective
        properties or the conduct of their respective businesses as described in the Offering Memorandum, except where the failure to possess or make the same could not reasonably be expected, individually or in the aggregate, to have a Material Adverse
        Effect; and except as otherwise disclosed in the Offering Memorandum, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, certificate, permit or authorization.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(x)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Title to Properties.</font> Except as otherwise disclosed in the Offering Memorandum, the Company and its
        subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case
        free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&#160;do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)&#160;could
        not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">9</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(y)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Tax Law Compliance.</font> The Company and its subsidiaries have paid all U.S. federal, state, local and
        foreign taxes which are due and payable (except assessments against which appeals have been or will be promptly taken in good faith and as to which adequate reserves have been provided in accordance with GAAP) and filed all U.S. federal and
        material state, local and foreign tax returns required to be filed through the date hereof; and except as otherwise disclosed in the Offering Memorandum, there is no tax deficiency that has been, or could reasonably be expected to be, asserted
        against the Company or any of its subsidiaries or any of their respective properties or assets except for any tax deficiencies that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(z)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Investment Company Act.</font> The Company is not, and after giving effect to the offering and sale of
        the Notes and the application of the proceeds thereof, will not be, required to register as an &#8220;investment company&#8221; or an entity &#8220;controlled&#8221; by an &#8220;investment company&#8221; within the meaning of the Investment Company Act of 1940, as amended, and the
        rules and regulations of the Commission thereunder.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(aa)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Insurance.</font> The Company and its subsidiaries have insurance covering their respective properties,
        operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by companies of established repute engaged in the same or similar
        businesses; and neither the Company nor any of its subsidiaries has (i)&#160;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such
        insurance or (ii)&#160;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its
        business.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(bb)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Stabilization or Manipulation.</font> The Company has not taken and will not take, directly or
        indirectly, any action designed to or that might be reasonably expected to cause or result in stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Notes.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(cc)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Sarbanes-Oxley.</font> There is and has been no failure on the part of the Company or any of the
        Company&#8217;s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Sarbanes-Oxley Act</font>&#8221;), including Section&#160;402 related to loans and Sections 302 and 906 related to certifications.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">10</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(dd)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Internal Accounting Controls.</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> The Company and its subsidiaries maintain systems of &#8220;internal control over financial reporting&#8221; (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under
          the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
          statements for external purposes in accordance with GAAP, including, but not limited to internal accounting controls sufficient to provide reasonable assurance that (i)&#160;transactions are executed in accordance with management&#8217;s general or specific
          authorizations; (ii)&#160;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&#160;access to assets is permitted only in accordance with management&#8217;s
          general or specific authorization; (iv)&#160;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in
          eXtensible Business Reporting Language included or incorporated by reference in the Offering Memorandum and the Pricing Disclosure Package fairly present the information called for in all material respects and are prepared in accordance with the
          Commission&#8217;s rules and guidelines applicable thereto. Except as described in the Offering Memorandum, since</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the end of the Company&#8217;s most recent audited fiscal year, there has been (i) no material weakness in the Company&#8217;s internal control over financial reporting (whether or not remediated) and (ii) no change in the
          Company&#8217;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting (including any corrective actions with regard to significant
          deficiencies and material weaknesses). The Company&#8217;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&#160;all significant deficiencies and material weaknesses in the design or operation of internal
          controls over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information; and (ii)&#160;any fraud, whether or not material, that involves management or other
          employees who have a significant role in the Company&#8217;s internal controls over financial reporting.</font></font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ee)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Disclosure Controls and Procedures.</font> The Company has established and maintains and evaluates
        &#8220;disclosure controls and procedures&#8221; (as such term is defined in Rules 13a-15 and 15d-15 under the Exchange Act) and &#8220;internal control over financial reporting&#8221; (as such term is defined in Rules&#160;13a-15 and 15d-15 under the Exchange Act); such
        disclosure controls and procedures are designed to ensure that material information relating to the Company and its consolidated subsidiaries is made known to the Company&#8217;s Chief Executive Officer and its Chief Financial Officer by others within
        the Company or any of its subsidiaries, and such disclosure controls and procedures are effective to perform the functions for which they were established; the Company&#8217;s independent registered public accountants and the Audit Committee of the Board
        of Directors of the Company have been advised of: (i)&#160;all significant deficiencies or material weaknesses, if any, in the design or operation of internal controls which could adversely affect the Company&#8217;s ability to record, process, summarize and
        report financial data; and (ii)&#160;all fraud, if any, whether or not material, that involves management or other employees who have a role in the Company&#8217;s internal controls; all &#8220;significant deficiencies&#8221; and &#8220;material weaknesses&#8221; (as such terms are
        defined in Rule 1-02(a)(4) of Regulation S-X under the Securities Act) of the Company, if any, have been identified to the Company&#8217;s independent registered public accountants and are disclosed in the Offering Memorandum; the principal executive
        officer and principal financial officer of the Company have made all certifications required by the Sarbanes-Oxley Act and any related rules and regulations promulgated by the Commission, and the statements contained in each such certification are
        complete and correct; the Company, the subsidiaries and the Company&#8217;s directors and officers are each in compliance in all material respects with all applicable effective provisions of the Sarbanes-Oxley Act and the rules and regulations of the
        Commission and the New York Stock Exchange (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">NYSE</font>&#8221;) promulgated thereunder.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">11</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ff)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Margin Regulations.</font> The issuance, sale and delivery of the Notes will not violate Regulation T,
        Regulation U or Regulation X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(gg)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Environmental Laws.</font> Except as otherwise disclosed in the Offering Memorandum, (i)&#160;the Company and
        its subsidiaries (A)&#160;are, and at all prior times were, in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions and orders relating to the protection of human health or safety,
        the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Environmental Laws</font>&#8221;),
        (B)&#160;have received and are in compliance with all permits, licenses, certificates or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses, and (C)&#160;have not received notice of
        any actual or potential liability under or relating to any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge
        of any event or condition that would reasonably be expected to result in any such notice; (ii)&#160;there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of
        (i)&#160;and (ii)&#160;above, for any such failure to comply, or failure to receive required permits, licenses or approvals, or cost or liability, as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and
        (iii)&#160;except as otherwise disclosed in the Offering Memorandum, (A)&#160;there are no proceedings that are pending, or that are known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental
        entity is also a party, other than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (B)&#160;the Company and its subsidiaries are not aware of any issues regarding compliance with
        Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a Material Adverse Effect, and (C)&#160;none of
        the Company and its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. Except as otherwise disclosed in the Offering Memorandum, there has been no storage, generation, transportation, handling, treatment,
        disposal, discharge, emission, or other release of any kind of toxic wastes or hazardous substances, including, but not limited to, any naturally occurring radioactive materials, brine, drilling mud, crude oil, natural gas liquids and other
        petroleum materials, by, due to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company, any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could
        reasonably be expected to be liable) upon any of the property now or previously owned or leased by the Company or any of its subsidiaries, or upon any other property, in violation of any Environmental Laws or in a manner or to a location that could
        reasonably be expected to give rise to any liability under the Environmental Laws, except for any violation or liability which could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">12</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(hh)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ERISA.</font> Each employee benefit plan, within the meaning of Section&#160;3(3) of the Employee Retirement
        Income Security Act of 1974, as amended (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ERISA</font>&#8221;), for which the Company or any member of its &#8220;Controlled Group&#8221; (defined as any organization
        which is a member of a controlled group of corporations within the meaning of Section&#160;414 of the Internal Revenue Code of 1986, as amended (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Code</font>&#8221;))

        would have any liability (each, a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Plan</font>&#8221;) has been maintained in compliance with its terms and the requirements of any applicable statutes,
        orders, rules and regulations, including but not limited to ERISA and the Code except for any noncompliance which could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.&#160; In addition, (i)&#160;no prohibited
        transaction, within the meaning of Section&#160;406 of ERISA or Section&#160;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (ii)&#160;for each Plan that is subject to
        the funding rules of Section&#160;412 of the Code or Section&#160;302 of ERISA, there has been no failure to satisfy the minimum funding standard of Section&#160;412 of the Code, whether or not waived, and none is reasonably expected to occur; (iii)&#160;the fair
        market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (iv)&#160;no &#8220;reportable event&#8221; (within the meaning of Section&#160;4043(c) of ERISA)
        has occurred or is reasonably expected to occur with respect to any Plan; and (v)&#160;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than
        contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a &#8220;multiemployer plan&#8221;, within the meaning of Section&#160;4001(a)(3) of ERISA).</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Labor Disturbance.</font> No labor disturbance by or dispute with employees of the Company or any of
        its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#8217; principal
        suppliers, contractors or customers, except, in each case, as could not reasonably be expected to have a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(jj)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Unlawful Payments.</font> None of the Company, any of its subsidiaries or, to the knowledge of the
        Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries, is aware of or has taken any action, directly or indirectly, that would result in a violation by such entities or
        persons of any applicable anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FCPA</font>&#8221;), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any
        money or anything of value to any &#8220;foreign official&#8221; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company, its
        subsidiaries and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and any other applicable anti-corruption laws, and have instituted and maintain policies and procedures designed to
        ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">13</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(kk)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Conflict with Money Laundering Laws.</font> The operations of the Company and its subsidiaries are and
        have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the USA Patriot Act, the Bank Secrecy Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and
        regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Money Laundering Laws</font>&#8221;); and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator or non-governmental authority involving the Company or any of its
        subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ll)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Conflict with Sanctions Laws.</font> Neither the Company nor any of its subsidiaries, nor, to the
        knowledge of the Company, any director, officer, agent, employee or affiliate thereof, is currently the subject of any sanctions administered or enforced by the Office of Foreign Assets Control of the United States Treasury Department, the U.S.
        Department of Commerce, the U.S. Department of State, the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury or any other relevant sanctions authority (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Sanctions</font>&#8221;); and the Company will not directly or indirectly use the proceeds of the offering of the Notes contemplated hereby, or lend, contribute or otherwise make available such proceeds to any
        subsidiary, joint venture partner or other person or entity: (i) to fund or facilitate any activities of or business with any person that is the target of Sanctions; (ii) to fund or facilitate any activities of or business in any country or
        territory that is the subject of comprehensive Sanctions; or (iii) in any other manner that will result in a violation by any person of Sanctions.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(mm)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Forward-Looking Information.</font> No &#8220;forward-looking statement&#8221; (within the meaning of
        Section&#160;27A of the Securities Act or Section&#160;21E of the Exchange Act) contained in the Offering Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(nn)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Statistical and Market-Related Data.</font> Nothing has come to the attention of the Company that has
        caused the Company to believe that the statistical and market-related data included or incorporated by reference in the Offering Memorandum is not based on or derived from sources that are reliable and accurate in all material respects.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(oo)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">USA Patriot Act.</font> The Company acknowledges that, in accordance with the requirements of the USA
        Patriot Act, the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as
        other information that will allow the Initial Purchasers to properly identify their respective clients.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(pp)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Restrictive Agreements.</font> Except as otherwise disclosed in the Offering Memorandum, no subsidiary
        of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#8217;s capital
        stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#8217;s properties or assets to the Company or any other subsidiary of the Company.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">14</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(qq)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Health Care Law Filings and Licensure.</font> Except as set forth in or contemplated in the Offering
        Memorandum, all reports, documents, claims, notices or approvals required to be filed, obtained, maintained or furnished pursuant to any Health Care Law (as defined below) or as otherwise required by the Centers for Medicare&#160;&amp; Medicaid
        Services, Medicare, any applicable state Medicaid, the Children&#8217;s Health Insurance Program or other state or commonwealth programs (each a &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Government
          Program</font>&#8221;), or applicable state or commonwealth departments of insurance, managed care, health and/or public health or any other governmental authority, have been so filed, obtained, maintained or furnished, and all such reports, documents,
        claims and notices were complete and correct in all material respects on the date filed (or were corrected in or supplemented by a subsequent filing), except where the failure to do so could not reasonably be expected, individually or in the
        aggregate, to have a Material Adverse Effect. Each of the Company and its subsidiaries which is licensed to conduct the business of health insurance or of a health maintenance organization is in current compliance with applicable deposit, reserve,
        risk based or other capital requirements imposed by each applicable state or commonwealth department of insurance or managed care. Additionally, the Company and each such subsidiary of the Company currently maintains all cash, marketable securities
        or other assets required to be retained by the Company or any of its subsidiaries pursuant to any applicable Health Care Laws, including any state or commonwealth statutory capital reserve requirements. None of the Company, its subsidiaries, nor,
        to the knowledge of the Company, any officer, director, employee or other agent of the Company or any of its subsidiaries, has engaged on behalf of the Company or such subsidiary in any of the following: (i)&#160;knowingly and willfully making or
        causing to be made a false statement or representation of a material fact in any applications for any benefit or payment under a Government Program or from any third party (where applicable federal, state or commonwealth law prohibits such payments
        to third parties); (ii)&#160;knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or payment under a Government Program or from any third party (where
        applicable federal, state or commonwealth law prohibits such payments to third parties); (iii)&#160;knowingly and willfully failing to disclose knowledge by a claimant of the occurrence of any event affecting the initial or continued right to any
        benefit or payment under a Government Program or from any third party (where applicable federal, state or commonwealth law prohibits such payments to third parties) on its own behalf or on behalf of another, with intent to secure such benefit or
        payment fraudulently; (iv)&#160;knowingly and willfully offering, paying, soliciting or receiving any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind (A)&#160;in return for referring an
        individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part by a Government Program or plan or any third party (where applicable federal, state or commonwealth
        law prohibits such payments to third parties), or (B)&#160;in return for purchasing, leasing or ordering or arranging for or recommending the purchasing, leasing or ordering of any good, facility, service, or item for which payment may be made in whole
        or in part by a Government Program or plan or any third party (where applicable federal, state or commonwealth law prohibits such payments to third parties).</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">15</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(rr)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Government Programs and Health Care Laws.</font> To the extent required in connection with their
        respective businesses, each of the Company and its subsidiaries is in compliance with each of its contracts and all other conditions of participation in a Government Program in the state(s) or commonwealth in which such entity operates, except
        where failure to be in compliance could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; neither the Company nor any of its subsidiaries is subject to any pending, or, to the knowledge of the Company,
        threatened or contemplated action, audit or investigation which could reasonably be expected to result in a revocation, suspension, termination, restriction or non-renewal of any third-party payor participation agreement or the Company&#8217;s or any
        significant subsidiary&#8217;s participation in any Government Program; and the Company and each significant subsidiary has been in compliance with all applicable Health Care Laws, except as set forth in or contemplated in the Offering Memorandum and
        except to the extent that failure to be in compliance could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. For purposes of this Agreement, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Health Care Laws</font>&#8221; shall mean all federal, state, commonwealth and local laws governing managed care organizations, health maintenance organizations, health insurance or other risk bearing entity,
        for the payment of health care services, including, without limitation: (i)&#160;Titles XVIII and XIX of the Social Security Act, governing the Medicare and Medicaid programs and regulations pertaining thereto, and all state and commonwealth laws and
        regulations governing the Medicaid programs; (ii)&#160;Sections 1320a-7, 1320a-7a and 1320a-7b of Title 42 of the United States Code; (iii)&#160;the False Claims Act, 31 U.S.C. Sections 3729-3733; (iv)&#160;the Stark law, 42 U.S.C. &#167; 1395nn; (v)&#160;the Federal
        Criminal False Claims Act, 18 U.S.C. &#167; 287; (vi)&#160;the False Statements Relating to Health Care Matters statute, 18 U.S.C. &#167; 1035; (vii)&#160;the Health Care Fraud statute, 18 U.S.C. &#167; 1347; (viii)&#160;the Health Insurance Portability and Accountability Act
        of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, their implementing regulations at 45 C.F.R. Parts 160 and 164 and applicable state and commonwealth health care privacy and security laws; (ix)&#160;any
        fee-splitting statutes and corporate practice of medicine laws and regulations in the states and commonwealth in which the Company and each significant subsidiary operates a community clinic; (x)&#160;any and all other similar laws; and (xi) the
        regulations promulgated pursuant to each of (i)&#160;through (x), each as amended from time to time. The Company and each subsidiary have taken reasonable actions designed to ensure that they do not allow any individual with an ownership or control
        interest (as defined in 42 U.S.C. &#167; 1320a-3(a)(3)) in the Company or any subsidiary or any officer, director or managing employee (as defined in 42 U.S.C. &#167;&#160;1320a-5(b)) of the Company or any subsidiary who would be a person debarred, suspended or
        excluded from participation in any federal health care program (as defined in 42 U.S.C. &#167; 1320a-7b(f)) as described in 42 U.S.C. &#167; 1320a- 7(b)(8) maintained by the Company or any significant subsidiary; and the Company and its significant
        subsidiaries, through their corporate and regulatory compliance program(s), have structured their respective business practices in a manner reasonably designed to comply with the federal, state and commonwealth laws regarding physician ownership of
        (or financial relationship with), the referral to entities providing, healthcare related goods or services, and laws requiring disclosure of financial interests held by physicians in entities to which they may refer patients for the provisions of
        health care related goods and services, and the Company reasonably believes that it is in material compliance with such laws. There are no proceedings that are pending, or that are known by the Company to be contemplated, against the Company or any
        of its subsidiaries under any Health Care Laws in which a governmental entity is also a party, other than such proceedings that could not reasonably be expected to have a Material Adverse Effect. Except as otherwise disclosed in the Offering
        Memorandum, neither the Company, nor any of its subsidiaries, has any material outstanding overpayments or refunds due under the Government Program contracts.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">16</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ss)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Business with Cuba.</font> The Company has complied with all provisions of Section&#160;517.075, Florida
        Statutes (Chapter 92-198, Laws of Florida) relating to doing business with the Government of Cuba or with any person or affiliate located in Cuba.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(tt)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Regulation S.</font> The Company and its Affiliates and all persons acting on their behalf (other than
        the Initial Purchasers, as to whom the Company makes no representation) have complied with and will comply with the offering restrictions requirements of Regulation&#160;S in connection with the offering of the Notes outside the United States and, in
        connection therewith, the Offering Memorandum will contain the disclosure required by Rule&#160;902 under the Securities Act. The Company is a &#8220;reporting issuer&#8221;, as defined in Rule&#160;902 under the Securities Act.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(uu)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No</font>&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Registration

          Rights.</font> Except as described in the Offering Memorandum, there are no contracts, agreements or understandings between the Company and any person granting such person the right (other than rights that have been waived in writing or otherwise
        satisfied) to require the Company to file a registration statement under the Securities Act with respect to any securities of the Company owned or to be owned by such person or in any securities being registered pursuant to any other registration
        statement filed by the Company under the Securities Act.</font></div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(vv)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IT Systems and Data.</font>&#160; Except as otherwise disclosed in the Offering Memorandum, (A) there has been
        no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to any of the Company&#8217;s and its subsidiaries&#8217; information technology and computer systems, networks, hardware, software, data and databases
        (including the data and information of their respective customers, employees, suppliers, vendors and any third-party data maintained, processed or stored by the Company and its subsidiaries, and any such data processed or stored by third parties on
        behalf of the Company and its subsidiaries), equipment or technology (collectively, &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IT Systems and Data</font>&#8221;) that could reasonably be expected to
        have a Material Adverse Effect; (B) none of the Company and its subsidiaries has been notified of, and each of them has no knowledge of any event or condition that could result in, any security breach or incident, unauthorized access or disclosure
        or other compromise to their IT Systems and Data that could reasonably be expected to have a Material Adverse Effect; and (C) the Company and its subsidiaries have implemented appropriate controls, policies, procedures, and technological safeguards
        designed to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory standards. Except as
        otherwise disclosed in the Offering Memorandum, (i) the Company and its subsidiaries are, and for the past three (3) years have been, in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court
        or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access,
        misappropriation or modification (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Data Protection Obligations</font>&#8221;) except for any such noncompliance that could not reasonably be expected to have
        a Material Adverse Effect; (ii) to ensure compliance with the Data Protection Obligations, the Company and its subsidiaries have in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects
        with their policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal Data (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Policies</font>&#8221;); (iii) neither the Company nor any of&#160; its subsidiaries has received any notification of or complaint regarding and neither the Company nor any of its subsidiaries is aware of any other facts that,
        individually or in the aggregate, would reasonably indicate non-compliance with any Data Protection Obligation other than any such noncompliance that could not reasonably be expected to have a Material Adverse Effect; (iv)&#160; there is no action, suit
        or proceeding by or before any court or governmental agency, authority or body pending or, to the knowledge of the Company, threatened alleging non-compliance with any Data Protection Obligation that, individually or in the aggregate, if determined
        adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; and (v) the execution, delivery and performance of this Agreement will not result in a breach of any Data Protection Obligation of
        the Company or any of its subsidiaries except for such breaches that could not reasonably be expected to have a Material Adverse Effect. The Company and its subsidiaries have at all times made all disclosures to users or customers required by
        applicable laws and regulatory rules or requirements, except where the failure to make such disclosures could not reasonably be expected to have a Material Adverse Effect, and none of such disclosures made or contained in any Policy have, to the
        knowledge of the Company, been inaccurate or in violation of any applicable Data Protection Obligations in any material respect.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">17</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any certificate signed by an officer of the Company and delivered to the Initial Purchasers or to counsel for the Initial Purchasers shall
      be deemed to be a representation and warranty by the Company to each Initial Purchaser as to the matters set forth therein.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 3.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Covenants of the Company</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The Company further covenants and agrees with each
        Initial Purchaser as follows:</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Copies of the Offering Memorandum.</font> The Company will furnish to the Initial Purchasers and to
        counsel for the Initial Purchasers, without charge, as many copies of the Pricing Disclosure Package and the Final Offering Memorandum and any amendments and supplements thereto as they shall reasonably request.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Final Offering Memorandum; Amendments and Supplements.</font> The Company will prepare and deliver to the
        Initial Purchasers the Final Offering Memorandum in the form approved by the Representative. The Company will not amend or supplement the Final Offering Memorandum prior to the Closing Date unless the Representative shall previously have been
        furnished a copy of the proposed amendment or supplement a reasonable period of time prior to the proposed use or filing, and shall not have reasonably objected to such amendment or supplement. Before making, preparing, using, authorizing,
        approving or distributing any Company Additional Written Communication, the Company will furnish to the Representative a copy of such written communication for review and will not make, prepare, use, authorize, approve or distribute any such
        written communication to which the Representative reasonably objects.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">18</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amendments and Supplements to the Final Offering Memorandum and Other Securities Act Matters.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At any time prior to the Closing Date, if (i)&#160;any event occurs or condition exists as a result of which any of the Pricing Disclosure
      Package, as then amended or supplemented, could include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
      misleading or (ii)&#160;it is necessary to amend or supplement any of the Pricing Disclosure Package, to comply with applicable law, the Company will immediately notify the Initial Purchasers thereof and will prepare and (subject to this Section&#160;3)
      provide to the Initial Purchasers such amendments or supplements to any of the Pricing Disclosure Package so that the statements in any of the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances under
      which they were made, be misleading or so that any of the Pricing Disclosure Package will comply with applicable law.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to the completion of the placement of the Notes by the Initial Purchasers with the Subsequent Purchasers, if any event occurs or
      condition exists as a result of which it is necessary to amend or supplement the Final Offering Memorandum, as then amended or supplemented, in order to make the statements therein, in the light of the circumstances when the Final Offering Memorandum
      is delivered to a Subsequent Purchaser, not misleading, or if in the judgment of the Representative or counsel for the Initial Purchasers it is otherwise necessary to amend or supplement the Final Offering Memorandum to comply with applicable law,
      the Company agrees to promptly prepare (subject to this Section&#160;3) and provide at its own expense to the Initial Purchasers, amendments or supplements to the Final Offering Memorandum so that the statements in the Final Offering Memorandum as so
      amended or supplemented will not, in the light of the circumstances at the Closing Date and at the time of sale of the Notes, be misleading or so that the Final Offering Memorandum, as amended or supplemented, will comply with applicable law.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company hereby expressly acknowledges that the indemnification and contribution provisions of Section&#160;7 hereof are specifically
      applicable and relate to each offering memorandum, registration statement, prospectus, amendment or supplement referred to in this Section&#160;3.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Use of Proceeds.</font> The Company shall apply the net proceeds from the sale of the Notes as described
        under the caption &#8220;Use of Proceeds&#8221; in the Pricing Disclosure Package.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">The Depositary.</font> The Company will assist the Initial Purchasers and use commercially reasonable
        efforts to permit the Notes to be eligible for clearance and settlement through the facilities of the Depositary.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Additional Information.</font> So long as any of the Notes are &#8220;restricted securities&#8221; within the meaning
        of Rule 144(a)(3) under the Securities Act, at any time when the Company is not subject to Section&#160;13 or 15(d) of the Exchange Act, for the benefit of holders and beneficial owners from time to time of the Notes, the Company shall furnish, at its
        expense, upon request, to holders and beneficial owners of the Notes and prospective purchasers of the Notes information satisfying the requirements of Rule&#160;144A(d).</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">19</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Other Securities.</font> During the period of 60 days following the date hereof, the Company will not,
        without the prior written consent of BofAS (which consent may be withheld at the sole discretion of BofAS), directly or indirectly, sell, offer, contract or grant any option to sell, pledge, transfer or establish an open &#8220;put equivalent position&#8221;
        within the meaning of Rule 16a-1 under the Exchange Act, or otherwise dispose of or transfer, or announce the offering of, or file any registration statement under the Securities Act in respect of, any debt securities of the Company or securities
        exchangeable for or convertible into debt securities of the Company, except&#160;as contemplated by this Agreement, without BofAS&#8217; prior written consent.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Blue Sky Compliance.</font> The Company shall cooperate with the Representative and counsel for the
        Initial Purchasers to qualify or register (or to obtain exemptions from qualifying or registering) all or any part of the Notes for offer and sale under the securities laws of the several states of the United States, the provinces of Canada or any
        other jurisdictions designated by the Representative, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as required for the distribution of the Notes. The Company shall not be
        required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently qualified or where it would be subject to taxation as a foreign corporation.
        The Company will advise the Representative promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Notes for offering, sale or trading in any jurisdiction or any initiation or threat of any
        proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best efforts to obtain the withdrawal thereof at the earliest possible moment.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Integration.</font> The Company agrees that it will not and will cause its Affiliates, directly or
        through any agent, not to make any offer or sale of securities of the Company of any class if, as a result of the doctrine of &#8220;integration&#8221; referred to in Rule 502 under the Securities Act, such offer or sale would render invalid the sale of the
        Notes pursuant hereto.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(j)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No General Solicitation or Directed Selling Efforts.</font> The Company agrees that it will not and will
        not permit any of its Affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, as to which no covenant is given) to (i)&#160;solicit offers (other than any Permitted General Solicitation) for, or offer or sell,
        the Notes by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D without the prior written consent of the Representative or in any manner involving a public offering within the meaning
        of Section&#160;4(a)(2) of the Securities Act or (ii)&#160;engage in any directed selling efforts with respect to the Notes within the meaning of Regulation S, and the Company will and will cause all such persons to comply with the offering restrictions
        requirement of Regulation S with respect to the Notes.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(k)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Legended Securities.</font> Each certificate for Notes will bear the legend contained in &#8220;Notice to
        Investors&#8221; in the Preliminary Offering Memorandum for the time period and upon the other terms stated in the Preliminary Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(l)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Resales.</font> The Company will not, and will not permit any of its affiliates (as defined in Rule
        144A under the Securities Act) to, resell any of the Notes that have been acquired by any of them, other than pursuant to an effective registration statement under the Securities Act or in accordance with Rule 144 under the Securities Act.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">20</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(m)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Additional Issuer Information.</font> Subject to Section 3(b) hereof, prior to the completion of the
        placement of the Notes by the Initial Purchasers with the Subsequent Purchasers, the Company shall file, on a timely basis, with the Commission all reports and documents required to be filed under Sections 13 or 15 of the Exchange Act.
        Additionally, at any time when the Company is not subject to Sections 13 or 15 of the Exchange Act, for the benefit of holders and beneficial owners from time to time of the Notes, the Company shall furnish, at its expense, upon request, to holders
        and beneficial owners of the Notes and prospective purchasers of the Notes information satisfying the requirements of Rule&#160;144A(d).</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Representative on behalf of the several Initial Purchasers, may, in its sole discretion, waive in writing the performance by the
      Company of any one or more of the foregoing covenants or extend the time for their performance.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 4.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Conditions of the Obligations of the Initial Purchasers</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The obligations of the
        several Initial Purchasers to purchase and pay for the Notes shall be subject to the accuracy of the representations and warranties of the Company in Section&#160;2 hereof, in each case as of the date hereof and as of the Closing Date, as if made on and
        as of the Closing Date and to the timely performance by the Company of its covenants and other obligations hereunder, and to each of the following additional conditions:</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Comfort Letters.</font> The Initial Purchasers shall have received on each of the date hereof and the
        Closing Date a letter, dated the date hereof or the Closing Date, as the case may be, in form and substance satisfactory to the Initial Purchasers and counsel to the Initial Purchasers, from Ernst&#160;&amp; Young LLP, independent registered public
        accounting firm, containing statements and information of the type ordinarily included in accountants&#8217; &#8220;comfort letters&#8221; to underwriters with respect to the financial statements and certain financial information contained or incorporated in the
        Pricing Disclosure Package and Final Offering Memorandum; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font> that the letter shall use a &#8220;cut-off date&#8221; within three days of the date of such letter
        and that their procedures shall extend to financial information in the Final Offering Memorandum not contained or incorporated in the Pricing Disclosure Package. References to the Final Offering Memorandum in this paragraph with respect to either
        letter referred to above shall include any amendment or supplement thereto at the date of such letter.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Material Adverse Change.</font> For the period from and after the date of this Agreement and prior to
        the Closing Date, no event or condition of a type described in Section&#160;2(l) hereof shall have occurred or shall exist, the effect of which in the judgment of the Representative makes it impracticable or inadvisable to proceed with the offering,
        sale or delivery of the Notes on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Final Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">21</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Ratings Agency Change.</font> For the period from and after the date of this Agreement and prior to
        the Closing Date, there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential downgrading or of any review for a possible change that does not indicate the direction of the possible change, in
        the rating accorded the Company or any of its subsidiaries or any of their securities or indebtedness by any &#8220;nationally recognized statistical rating organization&#8221; as such term is used by the Commission in Section 15E under the Exchange Act.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opinion of Counsel for the Company.</font> On the Closing Date, the Initial Purchasers shall have
        received the favorable opinion, dated as of the Closing Date, of Boutin Jones Inc., counsel for the Company, in form and substance satisfactory to the Initial Purchasers and counsel to the Initial Purchasers, the form of which is attached as
        Exhibit&#160;A hereto.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(e)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opinion of Chief Legal Officer.</font> On the Closing Date, the Initial Purchasers shall have received
        the favorable opinion, dated as of the Closing Date, of Jeffrey D. Barlow, the Company&#8217;s Chief Legal Officer and Secretary, in form and substance satisfactory to the Initial Purchasers and counsel to the Initial Purchasers, the form of which is
        attached as Exhibit&#160;B hereto.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(f)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Opinion of Counsel for the Initial Purchasers.</font> On the Closing Date, the Initial Purchasers shall
        have received the favorable opinion, dated as of the Closing Date, of Latham &amp; Watkins LLP, counsel for the Initial Purchasers, with respect to such matters as may be reasonably requested by the Initial Purchasers.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(g)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Officer&#8217;s Certificate.</font> On the Closing Date, the Initial Purchasers shall have received a
        certificate, dated as of the Closing Date, executed by the Chief Executive Officer or Chief Financial Officer of the Company, to the effect set forth in Sections&#160;4(b) and 4(c) hereof, and further to the effect that: (i)&#160;the representations,
        warranties and covenants of the Company set forth in Section&#160;2 hereof were true and correct as of the date hereof and are true and correct as of the Closing Date with the same force and effect as though expressly made on and as of the Closing Date;
        and (ii)&#160; the Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(h)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indenture and Notes.</font> The Indenture shall have been duly executed and delivered by a duly
        authorized officer of the Company and the Trustee, and the Notes shall have been duly executed and delivered by a duly authorized officer of the Company and duly authenticated by the Trustee.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Use of Proceeds.&#160; </font>On the Closing Date, the Company shall apply the proceeds from the
        offerings as described under the caption &#8220;Use of Proceeds&#8221; in the Pricing Disclosure Package and the Final Offering Memorandum.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Additional Documents.</font> On or before the Closing Date, the Initial Purchasers and counsel for the
        Initial Purchasers shall have received such information, documents and opinions as they may reasonably request.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If any condition specified in this Section&#160;4 is not satisfied or waived by the Representative when and as required to be satisfied, this
      Agreement may be terminated by the Representative by notice to the Company at any time on or prior to the Closing Date, which termination shall be without liability on the part of any party to any other party, subject to survival of the provisions
      referenced in Section&#160;8 hereof.</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">22</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 5.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Offer and Sale Procedures</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> Each of the Initial Purchasers, on the one hand, and the
        Company, on the other hand, hereby agree to observe the following procedures in connection with the offer and sale of the Notes:</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Offers and sales of the Notes will be made only by the Initial Purchasers or Affiliates thereof qualified to do so in the jurisdictions in which such offers or sales are made. Other than offers
        pursuant to any Permitted General Solicitation, each such offer or sale of the Notes shall be made only to persons whom the offeror or seller reasonably believes to be Qualified Institutional Buyers or non-U.S. persons outside the United States to
        whom the offeror or seller reasonably believes offers and sales of the Notes may be made in reliance upon Regulation S upon the terms and conditions set forth in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Annex
            I</u></font> hereto, which <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Annex I</u></font> is hereby expressly made a part hereof.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Upon original issuance by the Company, and until such time as the same is no longer required under the applicable requirements of the Securities Act, the Notes (and all securities issued in exchange
        therefor or in substitution thereof) shall bear the following legend:</font></div>
    <div>&#160;</div>
    <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;THIS NOTE (OR ITS PREDECESSOR) WAS ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF
      1933, AS AMENDED (THE &#8220;SECURITIES ACT&#8221;), AND THIS NOTE MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS NOTE IS HEREBY NOTIFIED THAT THE SELLER OF THIS
      NOTE MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER.</div>
    <div>&#160;</div>
    <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">THE HOLDER OF THIS NOTE AGREES FOR THE BENEFIT OF THE COMPANY THAT (A)&#160;THIS NOTE MAY BE OFFERED, RESOLD, PLEDGED OR OTHERWISE TRANSFERRED,
      ONLY (I)&#160;TO THE COMPANY, (II) IN THE UNITED STATES TO A PERSON WHOM THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (III) TO
      AN INSTITUTIONAL &#8220;ACCREDITED INVESTOR&#8221; WITHIN THE MEANING OF RULE 501(a)(1), (2), (3), (7)&#160;AND (8)&#160;UNDER THE SECURITIES ACT THAT IS AN INSTITUTIONAL INVESTOR ACQUIRING THE NOTE FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF SUCH AN INSTITUTIONAL
      &#8220;ACCREDITED INVESTOR,&#8221; IN EACH CASE IN A MINIMUM PRINCIPAL AMOUNT OF $250,000, (IV) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 904 OF THE SECURITIES ACT, (V)&#160;PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE
      SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE) OR (VI) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH OF CASES (I)&#160;THROUGH (VI) IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE
      UNITED STATES, AND (B)&#160;THE HOLDER WILL, AND EACH SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THIS NOTE FROM IT OF THE RESALE RESTRICTIONS REFERRED TO IN (A)&#160;ABOVE.&#8221;</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">23</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Following the sale of the Notes by the Initial Purchasers to Subsequent Purchasers pursuant to the terms hereof, except as expressly set
      forth in Sections 7(b) and 7(d) hereof, the Initial Purchasers shall not be liable or responsible to the Company for any losses, damages or liabilities suffered or incurred by the Company for any reason, including any losses, damages or liabilities
      under the Securities Act, arising from or relating to any resale or transfer of any Security.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal;">SECTION 6.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Payment
        of Expenses.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, the Company will pay or cause to be paid all costs, fees and expenses incident to the
        performance of its obligations under this Agreement and in connection with the transactions contemplated hereby, including, without limitation: (i)&#160;all expenses incident to the preparation, issuance and delivery of the Notes, (ii)&#160;all costs and
        expenses related to the issuance and delivery of the Notes to the Initial Purchasers, including any transfer or other taxes payable thereon, (iii)&#160;all fees, disbursements and expenses of the Company&#8217;s counsel, the Company&#8217;s accountants and other
        advisors (if any) in connection with the issuance and sale of the Notes and the consummation of the Transactions and all other fees or expenses in connection with the preparation of the Pricing Disclosure Package, any Permitted General Solicitation
        and the Final Offering Memorandum and all amendments and supplements thereto, and the Transaction Documents, including all printing costs associated therewith, and the delivering of copies thereof to the Initial Purchasers, (iv)&#160;the fees and
        expenses of the Trustee, including the fees and disbursements of counsel for the Trustee in connection with the Indenture and the Notes, (v)&#160;all filing fees, attorneys&#8217; fees and expenses incurred by the Company or the Initial Purchasers in
        connection with qualifying or registering (or obtaining exemptions from the qualification or registration of) all or any part of the Notes for offer and sale under the securities laws of the several states of the United States, the provinces of
        Canada or other jurisdictions designated by the Initial Purchasers (including, without limitation, the cost of preparing, printing and mailing preliminary and final blue sky or legal investment memoranda and any related supplements to the Pricing
        Disclosure Package or the Final Offering Memorandum), (vi)&#160;any fees payable in connection with the rating of the Notes with the ratings agencies, (vii)&#160;any filing fees incident to, and any reasonable fees and disbursements of counsel to the Initial
        Purchasers in connection with the review by the Financial Industry Regulatory Authority (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">FINRA</font>&#8221;), if any, of the terms of the sale of the Notes,
        (viii) all fees and expenses (including reasonable fees and expenses of counsel) of the Company in connection with approval of the Notes by the Depositary for &#8220;book-entry&#8221; transfer, and the performance by the Company of its other obligations under
        this Agreement and (ix)&#160;all costs and expenses relating to investor presentations, including any &#8220;road show&#8221; presentations undertaken in connection with the marketing of the offering of the Notes, including, without limitation, expenses associated
        with the production of road show slides and graphics and fees and expenses of any consultants engaged in connection with the road show presentations. It is understood, however, that except as provided in this Section&#160;6 and Section&#160;8 hereof, the
        Initial Purchasers shall pay their own expenses, including the fees and disbursements of their counsel.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">24</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">If the sale of the Notes provided for herein is not consummated because any condition to the obligations of the Initial Purchasers set forth in Section&#160;5 hereof is not satisfied, because this Agreement
        is terminated pursuant to Section&#160;8 hereof or because of any failure, refusal or inability on the part of the Company to perform all obligations and satisfy all conditions on its part to be performed or satisfied hereunder other than by reason of a
        default by any of the Initial Purchasers, the Company will reimburse the Initial Purchasers upon demand for all reasonable out-of-pocket expenses (including, without limitation, fees and disbursements of counsel, printing expenses, travel expenses,
        postage, facsimile and telephone charges) that shall have been incurred by them in connection with the proposed purchase, offering and sale of the Notes.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal;">SECTION 7.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indemnification.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indemnification by the Company.</font> The Company agrees to indemnify and hold harmless each Initial
        Purchaser, its affiliates, directors, officers and employees, and each person, if any, who controls (within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act) any Initial Purchaser against any and all losses, claims,
        damages, liabilities or expenses, joint or several, to which such Initial Purchaser, affiliate, director, officer, employee or controlling person may become subject, under the Securities Act, the Exchange Act or other federal or state statutory law
        or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company or is otherwise permitted by paragraph (c) below), insofar as such losses, claims,
        damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out of or are based upon any untrue statement or alleged untrue statement of a material fact contained or incorporated in the Preliminary Offering
        Memorandum, the Pricing Supplement, any Company Additional Written Communication, any Permitted General Solicitation or the Final Offering Memorandum (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a
        material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and will reimburse each Initial Purchaser and each such affiliate, director, officer, employee or
        controlling person for any and all expenses (including the fees and disbursements of counsel chosen by BofAS) as such expenses are reasonably incurred by such Initial Purchaser or such affiliate, director, officer, employee or controlling person in
        connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that the Company will not be liable in any such case to the extent, but only to the extent, that any such loss, claim, damage, liability or expense
        arises out of or is based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information relating to such Initial Purchaser and furnished to the Company by such
        Initial Purchaser through the Representative expressly for use in the Preliminary Offering Memorandum, the Pricing Supplement, any Company Additional Written Communication or the Final Offering Memorandum (or any amendment or supplement thereto).
        The indemnity agreement set forth in this Section&#160;7(a) shall be in addition to any liabilities that the Company may otherwise have.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">25</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Indemnification by the Initial Purchasers.</font> Each Initial Purchaser agrees, severally and not
        jointly, to indemnify and hold harmless the Company, each of its affiliates, directors, officers and each person, if any, who controls the Company within the meaning of Section&#160;15 of the Securities Act or Section&#160;20 of the Exchange Act, against any
        and all losses, claims, damages, liabilities or expenses, as incurred, to which the Company or any such affiliate, director, officer or controlling person may become subject, under the Securities Act, the Exchange Act, or other federal or state
        statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Initial Purchaser or is otherwise permitted by paragraph (c)), insofar as such
        loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained or incorporated in the Preliminary Offering
        Memorandum, the Pricing Supplement, any Company Additional Written Communication or the Final Offering Memorandum (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary in order to make
        the statements therein, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was
        made in the Preliminary Offering Memorandum, the Pricing Supplement, any Company Additional Written Communication or the Final Offering Memorandum (or any amendment or supplement thereto), in reliance upon and in conformity with written information
        relating to such Initial Purchaser and furnished to the Company by such Initial Purchaser through the Representative expressly for use therein; and to reimburse the Company and each such director or controlling person for any and all expenses
        (including the fees and disbursements of counsel) as such expenses are reasonably incurred by the Company or such director or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim,
        damage, liability, expense or action. The Company hereby acknowledges that the only information that the Initial Purchasers through the Representative have furnished to the Company expressly for use in the Preliminary Offering Memorandum, the
        Pricing Supplement, any Company Additional Written Communication or the Final Offering Memorandum (or any amendment or supplement thereto) are the statements set forth in the fourth paragraph, the third sentence of the sixth paragraph and the
        eighth paragraph under the caption &#8220;Plan of Distribution&#8221; in the Preliminary Offering Memorandum and the Final Offering Memorandum. The indemnity agreement set forth in this Section&#160;7(b) shall be in addition to any liabilities that each Initial
        Purchaser may otherwise have.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">26</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Notices and Procedures.</font> Promptly after receipt by any person to whom indemnity may be available
        under this Section&#160;7 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">indemnified party</font>&#8221;) of notice of the commencement of any action, such indemnified party will, if a claim in respect
        thereof is to be made against any person from whom indemnity may be sought under this Section&#160;7 (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">indemnifying party</font>&#8221;), notify such
        indemnifying party in writing of the commencement thereof; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font> that the failure to so notify such indemnifying party will not relieve such indemnifying
        party from any liability which it may have to such indemnified party under this Section&#160;7 except to the extent that it has been materially prejudiced by such failure (through the forfeiture of substantive rights and defenses) and shall not relieve
        such indemnifying party from any liability that such indemnifying party may have to such indemnified party other than under this Section&#160;7. In case any such action is brought against any indemnified party and such indemnified party notifies the
        relevant indemnifying party of the commencement thereof, such indemnifying party will be entitled to participate therein and, to the extent that it may wish, to assume the defense thereof, jointly with any other indemnifying party similarly
        notified, with counsel reasonably satisfactory to such indemnified party; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, if the defendants in any such action (including impleaded parties) include both the indemnified party and the indemnifying party and the indemnified party shall have concluded that a conflict may arise between the
        positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those
        available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise participate in the defense of such action on behalf of such indemnified party or
        parties. After notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof and approval by the indemnified party of counsel appointed to defend such action, the indemnifying party will not be liable
        to such indemnified party under this Section&#160;7 for any legal or other expenses other than reasonable costs of investigation, subsequently incurred by such indemnified party in connection with the defense thereof, unless (i)&#160;the indemnified party
        shall have employed separate counsel in accordance with the proviso to the immediately preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the expenses of more than one separate counsel (together
        with local counsel (in each jurisdiction)), which shall be selected by BofAS (in the case of counsel representing the Initial Purchasers or their related persons), representing the indemnified parties who are parties to such action), (ii)&#160;the
        indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of commencement of the action or (iii)&#160;such indemnifying party has authorized the
        employment of counsel for such indemnified party at the expense of the indemnifying party. After such notice from an indemnifying party to an indemnified party, such indemnifying party will not be liable for the costs and expenses of any settlement
        of such action effected by such indemnified party without the written consent of such indemnifying party. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the
        indemnified party for fees and expenses of counsel as contemplated by (i), (ii) or (iii) of the third sentence of this paragraph, the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its
        written consent if (x)&#160;such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (y)&#160;such indemnifying party shall not have reimbursed the indemnified party in accordance with such
        request prior to the date of such settlement. An indemnifying party will not, without the prior written consent of the indemnified party, settle or compromise or consent to the entry of any judgment in any pending or threatened claim, action, suit
        or proceeding in respect of which indemnification may be sought hereunder (whether or not the indemnified party or any other person that may be entitled to indemnification hereunder is a party to such claim, action, suit or proceeding) unless such
        settlement, compromise or consent (i)&#160;includes an unconditional release of the indemnified party and such other persons from all liability arising out of such claim, action, suit or proceeding and (ii)&#160;does not include any statements as to or any
        findings of fault, culpability or failure to act by or on behalf of any indemnified party.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">27</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Contribution.</font> If the indemnification provided for in this Section&#160;7 is held to be unavailable to
        or otherwise insufficient, for any reason, to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or
        payable by such indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&#160;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one
        hand, and the Initial Purchasers, on the other hand, from the offering of the Notes pursuant to this Agreement or (ii)&#160;if the allocation provided by clause (i)&#160;above is not permitted by applicable law, in such proportion as is appropriate to
        reflect not only the relative benefits referred to in clause (i)&#160;above but also the relative fault of the Company, on the one hand, and the Initial Purchasers, on the other hand, in connection with the statements or omissions which resulted in such
        losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Initial Purchasers, on the other hand, in connection with the offering
        of the Notes pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Notes pursuant to this Agreement (before deducting expenses) received by the Company, and the total
        discount received by the Initial Purchasers bear to the aggregate initial offering price of the Notes. The relative fault of the Company, on the one hand, and the Initial Purchasers, on the other hand, shall be determined by reference to, among
        other things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company, on the one hand, or the Initial Purchasers, on the other
        hand, and the parties&#8217; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses
        referred to above shall be deemed to include, any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in subclauses (a)&#160;and (b)&#160;of this
        Section&#160;7 with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&#160;7; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that no additional notice shall be required with respect to any action for which notice has been given under Section&#160;7(c) hereof for purposes of
        indemnification. The Company and the Initial Purchasers agree that it would not be just and equitable if contribution pursuant to this Section&#160;7 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for
        such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to in this Section&#160;7. Notwithstanding the provisions of this Section&#160;7, no Initial Purchaser shall be required to contribute any
        amount in excess of the discount received by such Initial Purchaser in connection with the Notes distributed by it. No person guilty of fraudulent misrepresentation (within the meaning of Section&#160;11 of the Securities Act) shall be entitled to
        contribution from any person who was not guilty of such fraudulent misrepresentation. The Initial Purchasers&#8217; obligations to contribute pursuant to this Section&#160;7 are several, and not joint, in proportion to their respective commitments as set
        forth opposite their names in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font>. For purposes of this Section&#160;7, each affiliate, director, officer and employee of an Initial Purchaser and each
        person, if any, who controls an Initial Purchaser within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as such Initial Purchaser, and each director of the Company, and each person, if any, who
        controls the Company within the meaning of the Securities Act and the Exchange Act shall have the same rights to contribution as the Company.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">28</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 8.</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160; Termination of this Agreement</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The Representative may terminate this Agreement with
        respect to the Notes by notice to the Company at any time on or prior to the Closing Date in the event that the Company shall have failed, refused or been unable to perform in any material respect all obligations and satisfy in any material respect
        all conditions on its part to be performed or satisfied hereunder at or prior thereto or if, at any time: (i)&#160;trading or quotation in any of the Company&#8217;s securities shall have been suspended or limited by the Commission or by the NYSE, or trading
        in securities generally on either the Nasdaq Stock Market or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such quotation system or stock exchange by the Commission or
        FINRA; (ii)&#160;there has been a material disruption in commercial banking or securities settlement, payment or clearance services in the United States; (iii)&#160;a general banking moratorium shall have been declared by any of federal or New York
        authorities; (iv)&#160;there shall have been (A)&#160;an outbreak or escalation of hostilities between the United States and any foreign power, (B)&#160;an outbreak or escalation of any other insurrection or armed conflict involving the United States, (C)&#160;the
        occurrence of any other calamity or crisis involving the United States or (D)&#160;any change in general economic, political or financial conditions which has an effect on the U.S. financial markets that, in the case of any event described in this
        clause (iv), in the sole judgment of the Representative, makes it impracticable or inadvisable to proceed with the offer, sale and delivery of the Notes as disclosed in the Pricing Disclosure Package or the Final Offering Memorandum, exclusive of
        any amendment or supplement thereto; or (v)&#160;in the judgment of the Representative there shall have occurred or exist any event or condition a type described in Section&#160;2(l) hereof or any other loss, event or other calamity of such character as in
        the judgment of the Representative may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this Section&#160;8 shall be without
        liability on the part of (i)&#160;the Company to any Initial Purchaser, except that the Company shall be obligated to reimburse the expenses of the Initial Purchasers pursuant to Section&#160;6 hereof, (ii)&#160;any Initial Purchaser to the Company, or (iii)&#160;any
        party hereto to any other party except that the provisions of Section&#160;7 hereof shall at all times be effective and shall survive such termination.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 9.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Notices</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> All communications hereunder shall be in writing and, if sent to any of
        the Initial Purchasers, shall be delivered or sent by mail or transmitted and confirmed in writing by any standard form of telecommunication to BofA Securities, Inc., 1540 Broadway, NY, NY 10036, Facsimile: Attention: High Yield Legal Department,
        with a copy to Latham &amp; Watkins LLP, 885 Third Avenue, New York, NY 10022, Attention: Michael Benjamin and if sent to the Company, shall be delivered or sent by mail, telex or facsimile transmission and confirmed in writing to the Company at
        200 Oceangate, Suite 100, Long Beach, California 90802, Facsimile: 562-499-0612, Attention: Thomas Tran, Chief Financial Officer, with a copy to Boutin Jones Inc., 555 Capitol Mall, Suite 1500, Sacramento, California 95814, Facsimile: 916-441-7597,
        Attention: Iain Mickle.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">29</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 10.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Successors</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> This Agreement shall inure to the benefit of and be binding upon the
        parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates and employees of each Initial Purchaser referred to in Section&#160;7 hereof. Nothing in this Agreement is
        intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No Subsequent Purchaser of the Notes from any Initial Purchaser shall be
        deemed to be a successor merely by reason of such purchase.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 11.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Authority of the Representative</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> Any action by the Initial Purchasers hereunder may
        be taken by BofAS on behalf of the Initial Purchasers, and any such action taken by BofAS shall be binding upon the Initial Purchasers.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 12.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Partial Unenforceability</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The invalidity or unenforceability of any section,
        paragraph or provision of this Agreement shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or
        unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 13.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Governing Law; Consent to Jurisdiction</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> THIS AGREEMENT AND ANY CLAIM, CONTROVERSY
        OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED IN SUCH STATE WITHOUT REGARD TO CONFLICTS OF LAW
        PRINCIPLES THEREOF.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (&#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Related Proceedings</font>&#8221;) may be instituted in the federal courts of the United States of America located in the City and County of New York or the courts
      of the State of New York in each case located in the City and County of New York (collectively, the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Specified Courts</font>&#8221;), and each party irrevocably
      submits to the exclusive jurisdiction (except for suits, actions, or proceedings instituted in regard to the enforcement of a judgment of any Specified Court in a Related Proceeding, as to which such jurisdiction is non-exclusive) of the Specified
      Courts in any Related Proceeding. Service of any process, summons, notice or document by mail to such party&#8217;s address set forth above shall be effective service of process for any Related Proceeding brought in any Specified Court. The parties
      irrevocably and unconditionally waive any objection to the laying of venue of any Specified Proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any Specified Court that any Related
      Proceeding brought in any Specified Court has been brought in an inconvenient forum.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 14.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Waiver of Jury Trial</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The Company hereby irrevocably and unconditionally waives
        trial by jury in any legal action or proceeding relating to this Agreement.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">30</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 15.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Defaulting Initial Purchasers</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> If any of the several Initial Purchasers shall fail
        or refuse to purchase the Notes that it or they have agreed to purchase hereunder on the Closing Date, and the aggregate number of Notes which such defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase does not
        exceed 10% of the aggregate number of the Notes to be purchased on such date, the non-defaulting Initial Purchasers shall be obligated to purchase the Notes that such defaulting Initial Purchaser or Initial Purchasers agreed but failed to purchase
        on the Closing Date (the &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Remaining Notes</font>&#8221;) in the respective proportions that the principal amount of the Notes set opposite the name of each
        non-defaulting Initial Purchaser in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font> hereto bears to the total number of the Notes set opposite the names of all the non-defaulting Initial
        Purchasers in <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>Schedule A</u></font>, or in such other proportions as may be specified by the Initial Purchasers with the consent of the non-defaulting Initial
        Purchasers; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>provided</u></font>, <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><u>however</u></font>, that the non-defaulting Initial
        Purchasers shall not be obligated to purchase any of the Notes on the Closing Date if the total amount of Notes which the defaulting Initial Purchaser or Initial Purchasers agreed but failed or refused to purchase on such date exceeds 10% of the
        total amount of Notes to be purchased on the Closing Date, and no non-defaulting Initial Purchaser shall be obligated to purchase more than 110% of the amount of Notes that it agreed to purchase on the Closing Date pursuant to this Agreement. If
        the foregoing maximums are exceeded, the non-defaulting Initial Purchasers, or those other purchasers satisfactory to the Initial Purchasers who so agree, shall have the right, but not the obligation, to purchase, in such proportion as may be
        agreed upon among them, all the Remaining Notes. If the non-defaulting Initial Purchasers or other Initial Purchasers satisfactory to the Initial Purchasers do not elect to purchase the Remaining Notes, this Agreement shall terminate without
        liability of any party to any other party except that the provisions of Sections&#160;6 and 8 hereof shall at all times be effective and shall survive such termination. In any such case either the Initial Purchasers or the Company shall have the right
        to postpone the Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Final Offering Memorandum or any other documents or arrangements may be effected.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As used in this Agreement, the term &#8220;<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Initial

        Purchaser</font>&#8221; shall be deemed to include any person substituted for a defaulting Initial Purchaser under this Section&#160;15. Any action taken under this Section&#160;15 shall not relieve any defaulting Initial Purchaser from liability in respect of any
      default of such Initial Purchaser under this Agreement.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 16.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">No Advisory or Fiduciary Responsibility</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The Company acknowledges and agrees that:
        (i)&#160;the purchase and sale of the Notes pursuant to this Agreement, including the determination of the offering price of the Notes and any related discounts and commissions, is an arm&#8217;s-length commercial transaction between the Company, on the one
        hand, and the several Initial Purchasers, on the other hand, and the Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated by this Agreement; (ii)&#160;in
        connection with each transaction contemplated hereby and the process leading to such transaction each Initial Purchaser is and has been acting solely as a principal and is not the agent or fiduciary of the Company or its affiliates, stockholders,
        creditors or employees or any other party; (iii)&#160;no Initial Purchaser has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to any of the transactions contemplated hereby or the process leading
        thereto (irrespective of whether such Initial Purchaser has advised or is currently advising the Company on other matters) or any other obligation to the Company except the obligations expressly set forth in this Agreement; (iv)&#160;the several Initial
        Purchasers and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and the several Initial Purchasers have no obligation to disclose any of such interests by
        virtue of any fiduciary or advisory relationship; and (v)&#160;the Initial Purchasers have not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby, and the Company has consulted its own legal,
        accounting, regulatory and tax advisors to the extent deemed appropriate.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">31</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the several Initial
      Purchasers, or any of them, with respect to the subject matter hereof. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the several Initial Purchasers with respect to any
      breach or alleged breach of fiduciary duty.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 17.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Survival</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">.</font> The respective indemnities, rights of contribution, agreements,
        representations, warranties and other statements of the Company, its officers and the several Initial Purchasers set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made by or on
        behalf of any Initial Purchaser, the Company or any of their partners, employees, officers or directors or any controlling person, as the case may be, and will survive delivery of and payment for the Notes sold hereunder and any termination of this
        Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: normal;">SECTION 18.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Miscellaneous.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Entire Agreement.</font> This Agreement constitutes the entire agreement of the parties to this Agreement
        and supersedes all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Counterparts.</font> This Agreement may be executed in two or more counterparts, each one of which shall
        be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by telecopier, facsimile, other electronic transmission (i.e., a
        &#8220;pdf&#8221; or &#8220;tif&#8221;) or any electronic signature complying with the U.S. federal ESIGN Act of 2000 or the New York Electronic Signature and Records Act or other transmission method shall be effective as delivery of a manually executed counterpart
        thereof.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amendments and Waivers.</font> No amendment or waiver of any provision of this Agreement, nor any consent
        or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(d)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Headings.</font> The headings herein are included for convenience of reference only and are not intended
        to be part of, or to affect the meaning or interpretation of, this Agreement.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SECTION 19.</font>&#160; <font style="font-size: 10pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Recognition of the U.S.
        Special Resolution Regimes. </font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(a)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the event that any Initial Purchaser that is a Covered Entity (as defined below) becomes subject to a proceeding under a U.S. Special Resolution Regime (as defined below), the transfer from such
        Initial Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such
        interest and obligation, were governed by the laws of the United States or a state of the United States.</font></div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">32</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(b)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate (each, as defined below) of such Initial Purchaser becomes subject to a proceeding under a U.S. Special
        Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special
        Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(c)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For purposes of this Section 19, a &#8220;BHC Act Affiliate&#8221; has the meaning assigned to the term &#8220;affiliate&#8221; in, and shall be interpreted in accordance with, 12 U.S.C. &#167; 1841(k). &#8220;Covered Entity&#8221; means any
        of the following: (i) a &#8220;covered entity&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b); (ii) a &#8220;covered bank&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or (iii) a
        &#8220;covered FSI&#8221; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). &#8220;Default Right&#8221; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as
        applicable. &#8220;U.S. Special Resolution Regime&#8221; means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations
        promulgated thereunder.</font></div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">[Signature Pages Follow]</div>
    <div>&#160;</div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">33</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space
      provided below.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Very truly yours,</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="zcae038f0adcb4cbaa6642640948697ed" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td colspan="2" rowspan="1">MOLINA HEALTHCARE, INC.</td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">
              <div>&#160;</div>
            </td>
            <td style="width: 20%;">
              <div>&#160;</div>
            </td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%; padding-bottom: 2px;">By:<br>
            </td>
            <td style="width: 20%; border-bottom: 2px solid rgb(0, 0, 0);">/s/ <font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Thomas L. Tran</font></td>
            <td style="width: 25%; padding-bottom: 2px;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">Name:<br>
            </td>
            <td style="width: 20%;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Thomas L. Tran</font></td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%;">Title:<br>
            </td>
            <td style="width: 20%;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Chief Financial Officer</font></td>
            <td style="width: 25.00%;">
              <div>&#160;</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <br>
    </div>
    <div style="text-align: center;"><font style="font-style: italic;">[Signature Page to Purchase Agreement]</font><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The foregoing Agreement is hereby confirmed and accepted by the Initial Purchasers as of the date first above written.</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: small-caps;">BofA Securities, Inc.</div>
    <div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Acting on behalf of itself<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>and as the Representative of<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>the several Initial Purchasers</div>
    <div>&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">By:</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</font></div>
    <div>&#160;</div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">By:</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>/s/ Matthew Curtin</u></font></div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Name:</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Matthew Curtin</font></div>
    <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Title:</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Managing Director</font></div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div> <br>
    </div>
    <div style="text-align: center;"><font style="font-style: italic;">[Signature Page to Purchase Agreement]</font></div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>&#160;</div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SCHEDULE A</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z060f4764e98f4c3cb1ffdf1b59d92f2b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Initial Purchasers</div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
          <td valign="bottom" colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: right; font-family: &#38;quot; font-size: 10pt; font-weight: bold;">Aggregate Principal</div>
            <div style="text-align: right; font-family: &#38;quot; font-size: 10pt; font-weight: bold;">Amount of Notes to</div>
            <div style="text-align: right; font-family: &#38;quot; font-size: 10pt; font-weight: bold;">be Purchased</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BofA Securities, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">162,500,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Truist Securities, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">94,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Barclays Capital Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Deutsche Bank Securities Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">J.P. Morgan Securities LLC</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">MUFG Securities Americas Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; text-indent: -76.5pt; margin-left: 76.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Wells Fargo Securities, LLC</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,250,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Citizens Capital Markets, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,000,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Fifth Third Securities, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.1pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,000,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Huntington Securities, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.02pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,000,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%; padding-bottom: 2px;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">U.S. Bancorp Investments, Inc.</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.02pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,000,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; width: 78%;">
            <div style="text-align: left; margin-left: 22.5pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Total</font><font id="TRGRRTFtoHTMLTab" style="text-indent: 0px; font-size: 5.05pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%;">&#160;</td>
          <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</font></div>
          </td>
          <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 19%;">
            <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">650,000,000</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%Schedule B-1-%%-->
    <div>&#160;</div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SCHEDULE B-1</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 10pt; font-weight: bold;">PRICING SUPPLEMENT</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Supplement Dated November 2, 2020 to<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>Preliminary Offering Memorandum Dated November 2, 2020</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">$650,000,000</div>
    <div style="text-align: center;">&#160;<img src="logo.jpg"></div>
    <div style="text-align: center; margin-right: 166.5pt; margin-left: 176pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Molina Healthcare, Inc.</div>
    <div style="text-align: center; margin-right: 144pt; margin-left: 153pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3.875% Senior Notes due 2030</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This Supplement is qualified in its entirety by reference to the Preliminary Offering Memorandum dated November 2, 2020 (the &#8220;Preliminary Offering
      Memorandum&#8221;). The information in this Supplement updates and supersedes any information in the Preliminary Offering Memorandum that is inconsistent or prepared based on assumptions that are inconsistent with the information below.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The notes have not been registered under the federal securities laws or the securities laws of any state. The initial purchasers named below are offering the
      notes only to persons reasonably believed to be qualified institutional buyers under Rule 144A and to persons outside the United States under Regulation S.&#160; See &#8220;Notice to Investors&#8221; in the Preliminary Offering Memorandum for additional information
      about eligible offerees and transfer restrictions. Investing in the notes involves risks that are described in the &#8220;Risk Factors&#8221; section beginning on page 15 of the Preliminary Offering Memorandum.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unless otherwise indicated, terms used but not defined herein have the meaning assigned to such terms in the Preliminary Offering Memorandum.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Other information (including financial information) presented in the Preliminary Offering Memorandum is deemed to have changed to the
      extent affected by the changes and other information described below.</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5687960d14a7459981e09608fef5808c">

        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Issuer:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Molina Healthcare, Inc.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Rating:<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup></div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ba3/BB-</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title of Notes:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.875% Senior Notes due 2030</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate Principal Amount:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$650,000,000</div>
          </td>
        </tr>

    </table>
    <div><br>
      <hr noshade="noshade" align="left" style="text-align: left; background-color: #000000; border: 0px; height: 1px; width: 2in; margin-left: 0pt; margin-right: auto; color: #000000;">
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">1</sup> A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time. Credit
        ratings are subject to change depending on financial and other factors.</div>
    </div>
    <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Schedule B-1-1</font></div>
      <div id="DSPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Proceeds to Issuer:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$650,000,000</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Final Maturity Date:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 15, 2030</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Issue Price:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100.0%, plus accrued interest, if any, from November 16, 2020</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Coupon:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.875%</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Yield to Maturity:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.875%</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Interest Payment Dates:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 15 and November 15</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Record Dates:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 1 and November 1</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First Interest Payment Date:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">May 15, 2021</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Optional Redemption:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to August 17, 2030 (90 days before maturity), the notes will be redeemable at any time or from time to time in whole or in part at our option
              at a redemption price described in &#8220;Description of Notes&#8212;Optional Redemption.&#8221;</div>
            <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <br>
            </div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On or after August 17, 2030 (90 days before maturity), the notes will be redeemable at any time in whole or from time to time in part at our option,
              at a redemption price equal to 100% of the principal amount of the notes being redeemed, plus accrued and unpaid interest thereon to, but excluding, the date of redemption.</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Joint Book-Running Managers:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BofA Securities, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Truist Securities, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Barclays Capital Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deutsche Bank Securities Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">J.P. Morgan Securities LLC</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MUFG Securities Americas Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wells Fargo Securities, LLC</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;">&#160;</td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Co-Managers:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Citizens Capital Markets, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fifth Third Securities, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Huntington Securities, Inc.</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">U.S. Bancorp Investments, Inc</div>
          </td>
        </tr>
        <tr>
          <td rowspan="1" style="width: 39.66%; vertical-align: top;"><br>
          </td>
          <td rowspan="1" style="width: 60.34%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Trade Date:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 2, 2020</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Schedule B-1-2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Settlement Date:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 17, 2020 (T+10)</div>
            <div>&#160;</div>
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company expects that delivery of the notes will be made against payment therefor on or about the 10th business day following the date of
              confirmation of orders with respect to the notes (this settlement cycle being referred to as &#8220;T+10&#8221;). Under Rule 15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the
              parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the notes before the notes are delivered will be required, by virtue of the fact that the notes initially will settle in T+10, to specify an
              alternative settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the notes who wish to trade the notes before their delivery should consult their own advisor.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 60.34%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Distribution:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">144A and Regulation S</div>
          </td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;" rowspan="1">&#160;</td>
          <td style="width: 60.34%; vertical-align: top;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 39.66%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CUSIP/ISIN Numbers:</div>
          </td>
          <td style="width: 60.34%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">144A CUSIP: 60855R AK6<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font>144A ISIN: US60855RAK68<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font>Regulation S CUSIP: U60868 AD5<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
              </font>Regulation S ISIN: USU60868AD52</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 1px; width: 15%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">The information presented in the Preliminary Offering Memorandum is deemed to have changed to the extent affected by the changes described
      herein.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">This material is confidential and is for your information only and is not intended to be used by anyone other than you. This information
      does not purport to be a complete description of these securities or the offering. Please refer to the Preliminary Offering Memorandum for a complete description.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">This communication is being distributed in the United States solely to persons reasonably believed to be qualified institutional buyers, as
      defined in Rule 144A under the Securities Act of 1933, as amended, and outside the United States solely to non-U.S. persons as defined under Regulation S.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">This communication is not an offer to sell the notes and it is not a solicitation of an offer to buy the notes in any jurisdiction where
      the offering is prohibited, where the person making the offer is not qualified to do so, or to any person who cannot legally be offered the notes.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
      automatically generated as a result of this communication being sent by Bloomberg or another system.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Schedule B-1-3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%Schedule B-%%-->
    <div><br>
    </div>
    <div></div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SCHEDULE B-2</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1. Press release of the Company dated November 2, 2020 relating to the announcement of the offering of the Notes.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2. Press release of the Company dated November 2, 2020 relating to the pricing of the offering of the Notes.</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Schedule B-2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%Exhibit A-%%-->
    <div>&#160;</div>
    <div></div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EXHIBIT A</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Opinion of counsel for the Company to be delivered pursuant to Section&#160;4 of the Purchase Agreement.</div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation. The Company has full corporate power and
        authority to own, lease and operate its properties and to conduct its business as described in the Pricing Disclosure Package and the Final Offering Memorandum and to enter into and perform its obligations under the Transaction Documents to which
        it is a party.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Purchase Agreement has been duly authorized, executed and delivered by the Company.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(iii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Indenture has been duly authorized, executed and delivered by the Company and (assuming the due authorization, execution and delivery thereof by the Trustee) is a valid and binding agreement of the
        Company, enforceable against the Company in accordance with its terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of
        creditors or by general equitable principles.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(iv)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Notes are in the form contemplated by the Indenture, have been duly authorized by the Company for issuance and sale pursuant to the Purchase Agreement and the Indenture and, when executed by the
        Company and authenticated by the Trustee in the manner provided in the Indenture (assuming the due authorization, execution and delivery of the Indenture by the Trustee) and delivered against payment of the purchase price therefor, will constitute
        valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws relating to
        or affecting enforcement of the rights and remedies of creditors or by general equitable principles and will be entitled to the benefits of the Indenture.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(v)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The statements in the Pricing Disclosure Package and the Final Offering Memorandum under the captions &#8220;Description of Other Indebtedness,&#8221; &#8220;Description of Notes,&#8221; and &#8220;Material U.S. Federal Income Tax
        Consequences,&#8221; insofar as such statements constitute matters of law, summaries of legal matters, documents or legal proceedings, or legal conclusions, have been reviewed by such counsel and fairly present and summarize, in all material respects,
        the matters referred to therein.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(vi)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">No consent, approval, authorization or other order of, or registration or filing with, any court or other governmental or regulatory authority or agency, is required for the execution, delivery and
        performance of the Transaction Documents by the Company to the extent a party thereto, or the issuance and delivery of the Notes, or consummation of the transactions contemplated hereby and thereby and by the Pricing Disclosure Package and the
        Final Offering Memorandum, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act, applicable state securities or blue sky laws.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit A-1</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(vii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The execution and delivery of the Transaction Documents by the Company and the performance by the Company to the extent a party thereto of its obligations thereunder (other than performance under the
        indemnification sections of the Purchase Agreement, as to which no opinion need be rendered): (i)&#160;will not result in any violation of the provisions of the charter or by-laws of the Company or any subsidiary; (ii)&#160;will not constitute a breach of,
        or Default or a breach under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets of the Company or any of its subsidiaries pursuant to, that certain Credit Agreement, dated as of June 8, 2020, as
        amended and/or supplemented to the date hereof, by and among the Company, the other loan parties party thereto, the lenders party thereto and Truist Bank, as administrative agent, or any other existing debt instrument that has been filed by the
        Company with the Commission; or (iii)&#160;will not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any subsidiary.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(viii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company is not, and upon the issuance and sale of the Notes as herein contemplated and the application of the net proceeds therefrom as described in the Pricing Disclosure Package and the Final
        Offering Memorandum, will not be, an &#8220;investment company&#8221; within the meaning of Investment Company Act.</font></div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ix)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Assuming the accuracy of the representations, warranties and covenants of the Company and the Initial Purchasers contained herein, no registration of the Notes under the Securities Act, and no
        qualification of the indenture under the Trust Indenture Act with respect thereto, is required in connection with the purchase of the Notes by the Initial Purchasers or the initial resale of the Notes by the Initial Purchasers in the manner
        contemplated by the Purchase Agreement and the Pricing Disclosure Package and the Final Offering Memorandum. Such counsel need express no opinion, however, as to when or under what circumstances any Notes initially sold by the Initial Purchasers
        may be reoffered or resold.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In rendering such opinion, such counsel may rely as to matters involving the application of laws of any jurisdiction other than the General
      Corporation Law of the State of Delaware, the laws of the State of California or the federal law of the United States, to the extent they deem proper and specified in such opinion, upon the opinion (which shall be dated the Closing Date shall be
      satisfactory in form and substance to the Initial Purchasers, shall expressly state that the Initial Purchasers may rely on such opinion as if it were addressed to them and shall be furnished to the Initial Purchasers) of other counsel of good
      standing whom they believe to be reliable and who are satisfactory to counsel for the Initial Purchasers; provided, however, that such counsel shall further state that they believe that they and the Initial Purchasers are justified in relying upon
      such opinion of other counsel, and as to matters of fact, to the extent they deem proper, on certificates of responsible officers of the Company and public officials; provided, further, that in rendering the &#8220;enforceability&#8221; opinions set forth in
      paragraphs (iv)&#160;through (vi)&#160;above, such counsel may assume that the outcome of the matters covered by such opinions shall be the same under the laws of the State of California as under the laws of the State of New York.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit A-2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, such counsel shall state that they have participated in conferences with officers and other representatives of the Company,
      representatives of the independent public or certified public accountants for the Company and with representatives of the Initial Purchasers at which the contents of the Pricing Disclosure Package and the Final Offering Memorandum and related matters
      were discussed and, although such counsel is not passing upon and does not assume any responsibility for the accuracy, completeness or fairness of the statements contained in the Pricing Disclosure Package or the Final Offering Memorandum (other than
      as specified above), on the basis of the foregoing, nothing has come to their attention which would lead them to believe that the Pricing Disclosure Package, as of the Time of Sale, or that the Final Offering Memorandum, as of its date or at the
      Closing Date, contained or contains an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading
      (it being understood that such counsel need express no belief as to the financial statements or other financial data derived therefrom, included in the Pricing Disclosure Package or the Final Offering Memorandum or any amendments or supplements
      thereto).</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit A-3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%1%Exhibit B-%%-->
    <div>&#160;</div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">EXHIBIT B</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-variant: small-caps; font-weight: bold;">FORM OF OPINION OF JEFFREY D. BARLOW, CHIEF LEGAL OFFICER AND SECRETARY OF THE COMPANY</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November [&#160;&#160; ], 2020</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BofA Securities, Inc.<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>One Bryant Park<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>New York, New York 10036</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">as Representative of the several Initial Purchasers<font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><br>
      </font>named in Schedule A to the Purchase Agreement</div>
    <div>&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zb7f5a2a597e741ada9e67ccf2ce8dccc">

        <tr>
          <td style="width: 36pt;"><br>
          </td>
          <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Re:</td>
          <td style="width: auto; vertical-align: top; text-align: left;">
            <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><u>Molina Healthcare, Inc. &#8211; Issuance of $650,000,000 aggregate principal amount of 3.875% Senior Notes due 2030</u></div>
          </td>
        </tr>

    </table>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ladies and Gentlemen:</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I am the Chief Legal Officer and Secretary of Molina Healthcare, Inc., a Delaware corporation (the &#8220;Company&#8221;). This opinion is being delivered to you pursuant
      to Section&#160;4(e) of the Purchase Agreement, dated November 2, 2020 (the &#8220;Purchase Agreement&#8221;), between the Company and BofA Securities, Inc. (&#8220;BofAS&#8221; or the &#8220;Representative&#8221;), as representative of the Initial Purchasers named therein (the &#8220;Initial
      Purchasers&#8221;), with respect to the Initial Purchasers&#8217; purchase of the Notes from the Company as provided in Section&#160;1 of the Purchase Agreement. Capitalized terms used but not defined herein shall be used herein as defined in the Purchase Agreement.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In connection with rendering the opinions set forth herein, I have examined and relied on originals or copies, certified or otherwise identified to my
      satisfaction, of such corporate and other records, documents and other papers as I have deemed necessary or appropriate to examine for the purpose of this opinion.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In my examination I have assumed the genuineness of all signatures (including endorsements), the legal capacity of natural persons, the authenticity of all
      documents submitted to me as originals and the conformity to original documents of all documents submitted to me as certified or photostatic copies and the authenticity of the originals of such copies. In making my examination of documents executed
      by parties other than the Company, I have assumed that such parties had the power, corporate or other, to enter into and perform all obligations under such documents and have also assumed the due authorization by all requisite action, corporate or
      other, and execution and delivery by such parties of such documents and the validity and binding effect thereof. As to any facts material to this opinion which I did not independently establish or verify, I have relied upon statements and
      representations of the Company and its subsidiaries and their respective officers and other representatives and of public officials.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whenever a statement is qualified by &#8220;to my knowledge&#8221; or a similar phrase, it refers to my current actual knowledge after reasonable inquiry.</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit B-1</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I am admitted to the Bar in the State of California. I express no opinion as to the laws of any jurisdiction other than (i)&#160;the laws of the State of
      California, (ii)&#160;the General Corporation Law of the State of Delaware and (iii)&#160;the federal laws of the United States of America to the extent specifically referred to herein.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based upon the foregoing and subject to the limitations, qualifications, exceptions and assumptions set forth herein, I am of the opinion that:</div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(i)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company has been duly incorporated and is validly existing as a corporation in good standing under the laws of the State of Delaware.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company has corporate power and authority necessary to own, lease and operate its properties and to conduct its business as described in the Pricing Disclosure Package and the Final Offering Memorandum and to execute and deliver
        the Transaction Documents to which it is a party and perform its obligations thereunder.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(iii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company is duly qualified to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except
        where the failure so to qualify or to be in good standing would not result in a Material Adverse Effect.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(iv)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Each of the Purchase Agreement and the Indenture has been duly authorized, executed and delivered by the Company.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(v)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Notes are in the form contemplated by the Indenture and have been duly authorized by the Company for issuance and sale pursuant to the Purchase Agreement and the Indenture. The Notes have been duly executed and delivered by the Company.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(vi)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">To my knowledge, except as described in the Pricing Disclosure Package and the Final Offering Memorandum, there are not any legal, governmental, or regulatory investigations, actions, suits, proceedings, inquiries or investigations,
        pending to which the Company or any subsidiary is a party, or to which the property of the Company or any subsidiary is subject, before or brought by any court or governmental agency or body, domestic or foreign, which, individually or in the
        aggregate, could reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect the properties or assets thereof or the consummation of the transactions contemplated in the
        Purchase Agreement or the performance by the Company of its obligations thereunder or under any other Transaction Document to which it is a party; and to my knowledge, no such investigations, actions, suits or proceedings are threatened or
        contemplated by any governmental or regulatory authority or threatened by others.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit B-2</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(vii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The information in the Pricing Disclosure Package and the Final Offering Memorandum under &#8220;Description of Other Indebtedness&#8221; and &#8220;Description of Notes,&#8221; to the extent that it constitutes matters of law, summaries of legal matters,
        legal proceedings or legal conclusions, and the information in the Pricing Disclosure Package and the Final Offering Memorandum (including the documents incorporated therein) under &#8220;We operate in an uncertain political and judicial environment
        which creates uncertainties with regard to our future prospects.&#8221;, &#8220;A reversal of the Medicaid Expansion would have a negative impact on our business.&#8221;, &#8220;Our participation in the Marketplace creates certain risks which could adversely impact our
        business, financial position, and results of operations.&#8221;, If state regulators do not approve payments of dividends and distributions by our subsidiaries, it may negatively affect our ability to meet our debt service and other obligations.&#8221;, &#8220;Our
        use and disclosure of personally identifiable information and other non-public information, including protected health information, is subject to federal and state privacy and security regulations, and our failure to comply with those regulations
        or to adequately secure the information we hold could result in significant liability or reputational harm.&#8221;, and &#8220;We are subject to extensive fraud and abuse laws that may give rise to lawsuits and claims against us, the outcome of which may have
        a material adverse effect on our business, financial condition, cash flows, or results of operations.&#8221;, in each case under the caption &#8220;Risk Factors&#8221;; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Health
        Plans&#8212;Business Overview&#8221; has been reviewed by me and is correct in all material respects.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(viii)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">All descriptions in the Pricing Disclosure Package and the Final Offering Memorandum (including the documents incorporated therein) of contracts and other documents to which the Company or its subsidiaries are a party are accurate in
        all material respects.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(ix)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">No filing with, or authorization, approval, consent, license, order, registration, qualification or decree of, any court or governmental authority or agency, domestic or foreign is necessary or required in connection with the due
        authorization, execution and delivery of the Transaction Documents or for the offering, issuance, sale or delivery of the Notes.</font></div>
    <div>&#160;</div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(x)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The execution, delivery and performance of the Transaction Documents and the consummation of the transactions contemplated in the Transaction Documents and in the Pricing Disclosure Package and the Final Offering Memorandum (including the
        issuance and sale of the Notes and the use of the proceeds from the sale of the Notes as described in the Pricing Disclosure Package and the Final Offering Memorandum under the caption &#8220;Use of Proceeds&#8221;) and compliance by the Company with its
        obligations under the Transaction Documents to which it is a party do not and will not, whether with or without the giving of notice or lapse of time or both, conflict with or constitute a breach of, or default under, or result in the creation or
        imposition of any lien, charge or encumbrance upon any property or assets of the Company or any subsidiary pursuant to any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease or any other agreement or instrument,
        known to me, to which the Company or any subsidiary is a party or by which it or any of them may be bound, or to which any of the property or assets of the Company or any subsidiary is subject (except for such conflicts, breaches, defaults or
        liens, charges or encumbrances that would not have a Material Adverse Effect), nor will such action result in any violation of the provisions of the charter or by-laws of the Company or any subsidiary, or any applicable law, statute, rule,
        regulation, judgment, order, writ or decree, known to me, of any government, government instrumentality or court, domestic or foreign, having jurisdiction over the Company or any subsidiary or any of their respective properties, assets or
        operations.</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit B-3</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div> <br>
    </div>
    <div><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(xi)</font><font style="text-indent: 0px; font-size: 5.14pt;" id="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The Company is not required, and upon the issuance and sale of the Notes as herein contemplated and the application of the net proceeds therefrom as described in the Pricing Disclosure Package and the Final Offering Memorandum, will
        not be required, to register as an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.</font></div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nothing has come to my attention that would lead me to believe that the Pricing Disclosure Package (except for financial statements and schedules and other
      financial data included therein or omitted therefrom, as to which I make no statement), at the Time of Sale, contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light
      of the circumstances under which they were made, not misleading or that the Final Offering Memorandum (except for financial statements and schedules and other financial data included therein or omitted therefrom, as to which I make no statement), at
      its date and at the date hereof, included or includes an untrue statement of a material fact or omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made,
      not misleading.</div>
    <div>&#160;</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In rendering this opinion, I have relied as to matters of fact (but not as to legal conclusions), to the extent I have deemed proper, on certificates of
      responsible officers of the Company and public officials.</div>
    <div>&#160;</div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: left; margin-left: 423pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Very truly yours,</div>
    <div>&#160;</div>
    <div style="text-align: left; margin-left: 423pt; font-family: 'Times New Roman',Times,serif; font-size: 10pt;">Jeff D. Barlow</div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="text-align: center;" id="DSPFPageNumberArea"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: normal; font-style: normal;" id="DSPFPageNumber">Exhibit B-4</font></div>
      <div style="page-break-after: always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ANNEX I</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Each Initial Purchaser understands that:</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Such Initial Purchaser agrees that it has not offered or sold and will not offer or sell the Notes in the United States or to, or for the
      benefit or account of, a U.S. person (other than a distributor), in each case, as defined in Rule&#160;902 of Regulation&#160;S (i)&#160;as part of its distribution at any time and (ii)&#160;otherwise until 40 days after the later of the commencement of the offering of
      the Notes pursuant hereto and the Closing Date, other than in accordance with Regulation&#160;S or another exemption from the registration requirements of the Securities Act. Such Initial Purchaser agrees that, during such 40-day restricted period, it
      will not cause any advertisement with respect to the Notes (including any &#8220;tombstone&#8221; advertisement) to be published in any newspaper or periodical or posted in any public place and will not issue any circular relating to the Notes, except such
      advertisements as are permitted by and include the statements required by Regulation&#160;S.</div>
    <div>&#160;</div>
    <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Such Initial Purchaser agrees that, at or prior to confirmation of a sale of Notes by it to any distributor, dealer or person receiving a
      selling concession, fee or other remuneration during the 40-day restricted period referred to in Rule&#160;903 of Regulation&#160;S, it will send to such distributor, dealer or person receiving a selling concession, fee or other remuneration a confirmation or
      notice to substantially the following effect:</div>
    <div>&#160;</div>
    <div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8220;The Notes covered hereby have not been registered under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and may not be
      offered and sold within the United States or to, or for the account or benefit of, U.S. persons (i)&#160;as part of your distribution at any time or (ii)&#160;otherwise until 40 days after the later of the date the Notes were first offered to persons other
      than distributors in reliance upon Regulation&#160;S and the Closing Date, except in either case in accordance with Regulation S under the Securities Act (or in accordance with Rule&#160;144A under the Securities Act or to accredited investors in transactions
      that are exempt from the registration requirements of the Securities Act), and in connection with any subsequent sale by you of the Notes covered hereby in reliance on Regulation&#160;S under the Securities Act during the period referred to above to any
      distributor, dealer or person receiving a selling concession, fee or other remuneration, you must deliver a notice to substantially the foregoing effect. Terms used above have the meanings assigned to them in Regulation S under the Securities Act.&#8221;</div>
    <div><br>
    </div>
    <div>&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a52318785ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using EDGARfilings PROfile 7.2.0.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font> <br>
  </div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: right;"><font style="font-weight: bold;"> <br>
    </font></div>
  <div style="text-align: left;">
    <div class="bw-release">
      <div class="bw-release">
        <div class="bw-release">
          <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Molina Healthcare Announces Pricing of $650 Million of Senior Notes Due 2030</b> </h1>
          <div class="bw-release-body">
            <div class="bw-release-table-js bw-release-story">
              <p>LONG BEACH, Calif.--(BUSINESS WIRE)--November 2, 2020--Molina Healthcare, Inc. (NYSE: MOH) (the &#8220;Company&#8221;) today announced that it priced $650 million aggregate principal amount of its senior notes due 2030 (the &#8220;Notes&#8221;) to be sold in a
                private offering to individuals reasonably believed to be &#8220;qualified institutional buyers&#8221; pursuant to Rule 144A under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and to certain persons outside the United States in
                reliance on Regulation S under the Securities Act. The offering is expected to close on or about November 17, 2020 (such actual closing date, the &#8220;Settlement Date&#8221;), subject to the satisfaction of customary closing conditions. </p>
              <p> The Notes will not be guaranteed by any of the Company&#8217;s subsidiaries at the time of issuance. The Notes will bear interest at a rate of 3.875% per year. Interest will be payable semi-annually in arrears on May 15 and November 15 of each
                year, commencing May 15, 2021, and will accrue from the Settlement Date. The Notes will mature on November 15, 2030. </p>
              <p> The Company estimates that after deducting fees and expenses payable by the Company, the net proceeds from the issuance and sale of the Notes will be approximately $641 million (the &#8220;Net Proceeds&#8221;). The Company intends to use
                approximately $346 million of the Net Proceeds to redeem the entire $330 million outstanding principal amount of its 4.875% senior notes due 2025, and to pay related fees and expenses. The Company intends to use the remaining Net Proceeds
                for general corporate purposes, which may include repayment of indebtedness, share repurchases, funding for acquisitions, capital expenditures, additions to working capital and capital contributions to the Company&#8217;s health plan subsidiaries
                to meet statutory requirements in new or existing states. </p>
              <p> The Notes have not been registered under the Securities Act or any state securities laws and may not be offered or sold within the United States or to, or for the benefit of, a U.S. person (as defined in Regulation S) except in
                transactions exempt from, or not subject to, the registration requirements of the Securities Act. </p>
              <p> This press release shall not constitute an offer to sell or a solicitation of an offer to purchase the Notes and shall not constitute an offer, solicitation or sale in any state or jurisdiction where such offer, solicitation or sale is
                prohibited. </p>
              <p> <b>About Molina Healthcare</b> </p>
              <p> Molina Healthcare, Inc., a FORTUNE 500 company, provides managed health care services under the Medicaid and Medicare programs and through the state insurance marketplaces. Through its locally operated health plans, Molina Healthcare
                served approximately 4.0 million members as of September 30, 2020. For more information about Molina Healthcare, please visit www.molinahealthcare.com. </p>
              <div> </div>
              <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
                <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                  <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
              </div>
              <p> <b>Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995</b> </p>
              <p> This press release contains &#8220;forward-looking statements,&#8221; including statements related to the Company&#8217;s offering of the Notes and intended use of net proceeds of the offering, which are subject to risks and uncertainties, including,
                without limitation, risks related to whether the Company will consummate the offering of the Notes on the expected terms, or at all, market and other general economic conditions, and whether the Company will be able to satisfy the
                conditions required to close any sale of the Notes. Additional information regarding the risk factors to which the Company is subject is provided in greater detail in its periodic reports and filings with the Securities and Exchange
                Commission, including its annual report on Form 10-K for the year ended December 31, 2019 and in its quarterly reports on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020 and September 30, 2020. These reports can be accessed
                under the investor relations tab of the Company&#8217;s website at www.molinahealthcare.com or on the SEC&#8217;s website at www.sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will
                prove to be accurate, or that any other results or events projected or contemplated by its forward-looking statements will in fact occur, and it cautions investors not to place undue reliance on these statements. All forward-looking
                statements in this release represent the Company&#8217;s judgment as of the date hereof, and, except as otherwise required by law, the Company disclaims any obligation to update any forward&#8209;looking statements to conform the statement to actual
                results or changes in its expectations. </p>
            </div>
            <div class="bw-release-contact">
              <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
              <p> <b>Investor Contact: </b>Julie Trudell, Julie.Trudell@molinahealthcare.com, 562-912-6720 <br>
                <b>Media Contact:</b> Caroline Zubieta, Caroline.Zubieta@molinahealthcare.com, 562-951-1588 </p>
            </div>
          </div>
        </div>
      </div>
    </div>
    <font style="font-weight: bold;"> </font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>moh-20201102.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<xs:schema targetNamespace="http://molinahealthcare.com/20201102" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:moh="http://molinahealthcare.com/20201102" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="moh-20201102_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="moh-20201102_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://molinahealthcare.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>moh-20201102_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine2_lbl">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine3_lbl">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry_lbl" xml:lang="en-US" id="dei_EntityAddressCountry_lbl">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="EntityInformationFormerLegalOrRegisteredName" xlink:title="EntityInformationFormerLegalOrRegisteredName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xml:lang="en-US" id="dei_EntityInformationFormerLegalOrRegisteredName_lbl">Entity Information, Former Legal or Registered Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:title="label: EntityInformationFormerLegalOrRegisteredName to dei_EntityInformationFormerLegalOrRegisteredName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" id="dei_NoTradingSymbolFlag_lbl">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications_lbl" xml:lang="en-US" id="dei_WrittenCommunications_lbl">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:title="label: WrittenCommunications to dei_WrittenCommunications_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial_lbl" xml:lang="en-US" id="dei_SolicitingMaterial_lbl">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementTenderOffer_lbl">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer_lbl">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>moh-20201102_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 7.0.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://molinahealthcare.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="moh-20201102.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://molinahealthcare.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="EntityInformationFormerLegalOrRegisteredName" xlink:title="EntityInformationFormerLegalOrRegisteredName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInformationFormerLegalOrRegisteredName" xlink:title="presentation: CoverAbstract to EntityInformationFormerLegalOrRegisteredName" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !I 50# 2(  A$! Q$!_\0
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M10 4444 %&<UX_\ MO?M66W['WP-NO%3V?\ :5\\JV>GV9;:EQ</G:&;'"@
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M0<G% ^A^I(7%+1FB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC3XA^(_@W_P2PL=1\+Z]KWA[5XM=T:!;[2;U[24(9$#(74@X<?+CU->B6/\
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I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>a52318785_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20201102.xsd" xlink:type="simple"/>
    <context id="c20201102to20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-11-02</startDate>
            <endDate>2020-11-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20201102to20201102"
      id="Fact_e4854e4176cc4795843bdebcc4cbe14f">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20201102to20201102"
      id="Fact_7ae851094a934914bcf85dd04117b349">0001179929</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20201102to20201102"
      id="Fact_d8cb1846f79f49f6b29db51b424463c4">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20201102to20201102"
      id="Fact_ee9293229f2240309a8ff96e5eefb42d">2020-11-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20201102to20201102"
      id="Fact_5fce183580c84d2681f9e32b777bba3c">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20201102to20201102"
      id="Fact_fec0da96a2da44ad86783bd6f33141b6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20201102to20201102"
      id="Fact_0e218934daa7442285ff4eb4169c3b23">001-31719</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20201102to20201102"
      id="Fact_53de4d2dd0fb467ea031450800b4f30f">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20201102to20201102"
      id="Fact_b32e977aebaa40d6b4bcc1a1c577996e">200 Oceangate, Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20201102to20201102"
      id="Fact_3057238918424d12aff800096e7d679d">Long Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20201102to20201102"
      id="Fact_04d834502b3946c3b688edfa13f62e58">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20201102to20201102"
      id="Fact_29670d01a13a47899c9429aa69fb33a7">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20201102to20201102"
      id="Fact_2d1353d12f6644b4ba92b3cb9ac1bc23">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20201102to20201102"
      id="Fact_171c109229a6401aa3d49465df6e7ee3">435-3666</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20201102to20201102"
      id="Fact_e2934592738845ae85483090ff6fa4f7">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20201102to20201102"
      id="Fact_a1de93c62a724233956ffea0b70df45c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20201102to20201102"
      id="Fact_ab963e3bd8c642da80bb8f4d1af6ea42">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20201102to20201102"
      id="Fact_0b573b26bbcb4679854ba3da29919bfd">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20201102to20201102"
      id="Fact_2fa51f2167654174a37741aaf1559ea0">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20201102to20201102"
      id="Fact_be72255bb4ab4e73a1bcd9e4b8e74767">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20201102to20201102"
      id="Fact_479476c1029e405c991bd60482260061">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20201102to20201102"
      id="Fact_0a6beb63c12445c2927975a7c3ebfd0b">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139788894248616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  02,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate, Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04
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MYHOA/UY_ 5!+ 0(4 Q0    ( !$\8U$'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ $3QC449&>"OM
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ $3QC49E<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  1/&-1L\M,(CX$  !&$
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ $3QC48.II0/4 0  ,@8   T              ( !@ P  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    "  1/&-1EXJ[',     3 @  "P
M        @ %_#@  7W)E;',O+G)E;'-02P$"% ,4    "  1/&-1'#AEZC\!
M   \ @  #P              @ %H#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ $3QC420>FZ*M    ^ $  !H              ( !U!   'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ $3QC4660>9(9 0
MSP,  !,              ( !N1$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2      D "0 ^ @   Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="a52318785.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://molinahealthcare.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="a52318785.htm">a52318785.htm</File>
    <File>a52318785ex1_1.htm</File>
    <File>a52318785ex99_1.htm</File>
    <File>moh-20201102.xsd</File>
    <File>moh-20201102_lab.xml</File>
    <File>moh-20201102_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "a52318785.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "a52318785.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20201102_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20201102_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20201102.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 30,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "moh",
   "nsuri": "http://molinahealthcare.com/20201102",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a52318785.htm",
      "contextRef": "c20201102to20201102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://molinahealthcare.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "a52318785.htm",
      "contextRef": "c20201102to20201102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://molinahealthcare.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001157523-20-001422-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001157523-20-001422-xbrl.zip
M4$L#!!0    ( !$\8U$N05M%"18  .5[   -    834R,S$X-S@U+FAT;>T]
M:7/;QI+?MVK_PRQS/+E*)'$?LJPJ69(3;6Q))2F;['Y)#68&))Y!@!F EOA^
M_78/#H(D2%$2==C/JE1,<*Z>OKNG!]P?YJ.8W([B)-N[#60<O>L,\WR\U^_?
MW-ST\)M>*@=]0]/,?I1D.4V8Z)3]XRCYO*8[-@<TJ[O?+O6_,55OW??]OFJM
MNV916T>85N__^>GC%1N*$>TNPH/+\]G )C1.OVBLND99:AFZNVZS18]ZP.VJ
MOCHB!H 7?[Z__#CKGK?WGW7MYY(F69C*$<VC-,&9[*YF= VG,4DW$VQN(GCN
M#=(O=\[C=4V]FF>2=0>4CNMY0IH%"IBR 8?X74UO#.%B 8_5NM#0TGV2RY6H
M]/O06G5,)J/VCCR7_7PZ%GWH(63$Z@%ILL&8-.DNC&/I),GEM'T392-NQ)W?
M")M(*1*V:ES9VH*!A$8L:Q^EFEK6RB+6/@ :L+N^T#T?RQ7]H04'>/,#Q"T;
MM@_ EI8]9#)?YA'XLJ7K*)U-/4J!%>E0T#@?,BI%CZ4C&(([T(QRP&JQ1_W3
M.?C/_R!D'Z;@ZA-\SJ,\%@?[_>+?\LO_ZG;)QXB))!.<Y.D>>3_)0 JRC/P1
M25%T4G_'*0-V2'+"I* Y=,9^ W)R_,OA91@!N(.,7%R>PT=!W)[1TWI:8_11
M.I[*:##,"8!HDR[!S9#W,J5<1GP@2+=;0302.26XM:[X>Q)]>=<Y2I,<%NY>
M U]V""N>WG5R<9OWU59)'\;N]\N]PL<@Y5.2Y=-8O.N$T+\;TE$43_?(/ZZC
MD<C(F;@AE^F()O_8)>J;79(!IX=OB>J=1?\2>T37QOE;@JMT:1P-DCT2BQ"^
M86F<RCWR@Z;^WI* LL\#">S/NU53J/[>(@WV>?2%1/Q=Y_CJXD.$RN77B'.1
M="KX>)2-8PJP@<0)&+(?W>[A3H0L/JK>ZB-T."LDDB1TA$-%M'<(-.%(EP\Q
M'7342A\HR_\2EF=;PM)=AS'+]6W/,@,N GA@@="ML$3D;7XIPG<=5O%6GLZX
MK-!_[SJ@,_>"-(T%34(:@_$Y4/_L]^=@6@WB20(<-ST"&"6-3Q,N;G\3TP:H
M+A6>K6N^17W3\G4K8*%G<ZY9NNX&\,W=H!X (:"S[QO^$E3]>21*$0I4."([
MV$?SN)<IPP=3$V4N]X825P%A[%;3]VXSWBE;43>^ZV31:!P#'O;[\U,4JS67
M4(]9.I'J27D#>^5N% ):=U/V$PIOU5/$\3F,A"1J/=%JPXY.?YO'QN+@@^JK
M^=G'@*R45T_@ \C\&*3\ ('JHMHTJG&SMAI,OJ)KU5(]5XOTY_!0(:W&4K\A
M 7T0'R73H!B*CTI'H%"5\M,44%!CN9"E%*^6^4+D6R3>08E77]P(5%9[)$AC
M#D+Y^]GI]<DQN;H^O#ZY:@+U K!<G1S]?GEZ?7IR10[/CLG)GT>_'I[]<D*.
MSC]].KVZ.CT_VRJ =RG(-A#_H-D0#$*>)KODN'?4 VUO6_Z+@_77W-\+D_'#
M^>4GLE)G5M:VL'FUJN0>"W3/<D+7#RT_= +#YX&M!Y9A68[)K U4I=?];5E'
M?KN$60..L0H<LA](Y5.H]5\:FB/E(>?D4HQ3F;\X.*\+.1<3F4TH8"=/R95@
M&*T1W23GET2W=_@;DH8D'PILFL@HCV#!$W#4:0(>YR'+L5D'I^/%M_$B2%TI
MCFBT$34%QY&=ZEE0,-LBRXGX@@PI5;/@;_;(6?I%C )P3<S=PK/?N5.S72AG
MX*1P$9J.JP"_Q30,/S0,2S,UGWIAZ#O"%B($/<?OZ;ARF'T$ X:<3J>P ?"\
M#VIHC0+:17WX9ID"!S__H#O:VQ<GS5V:\BG@O+]MNR,4N!2#*,,42WX&+0W:
MVR$3NF?:GL8\BQN.IX>^,(W ==T@H";;P+Q].O]X>G9(?CTY_'C]Z]'AY<DN
M.3T[ZBV9O-<D;SLGM[![A284,UFCA]",9&/!T'/G)$I(E&<$U!=(G6QATF<&
M>YW2RFD0"U@\CK,Q9> +ONMH'?4\IIQ7STCX?UF<A<S5'-V!B-4QF$\=R^00
MJ')A,=ODG2U%\C<1SX?XH/T$07LJ(;[ @#VFXPSZ5)\VB/@[!U5B8Y;@4 %*
M+@\:*0]2H8)7&R@A,(V>IP,,7X3,(T;C:K$@S?-TU)B^^'L!RMXAOZ<)2R7H
M?I4<O<I!PQX5V;^CE#?%.11,X]1WJ,&I95'N.:YG!MP)35.W],"YGRK'O"U&
MG[D8R_0+PH2Z_%C$] ;4^CH!KS'9GX60U3<YWXQF5D_WOF::?8AB 6U@]1H$
MTH2A>^#_<$I=RS(,SPY#2P26[OC,# QSH\P+YC!=?3GQLF4"F#WMJQ:::WI[
M6F9AF!*<)6J KA-@]3C7P-%Q7$$U$!-;\S0ML$)3VR!E=Z";7<O00(LZ6R&'
MTFK].;7V;2FZ':6]2"I)"F&")/^$*"'C41%'@"E>QM"+@!DU%>Z;;UJ-[1RE
MHU&494@ U%FD$)-';?K5JXZ=T\LK<C(:Q^D4F'!>34!LU;M[]TN26OR+QR+*
M%6LD3K_N4.8>CB7S/,UU;4]8IF]QT_<"TZ?PT0VL %3LM^=8%A"\7C:_PT(>
M<BY%EI7_?(P2H3>L8V :PG==*@)*+8T[0$3&=*HSVW5]WQ$;6$=#T\@Y$S09
M@-+?)5>3"'0_(&W15N[.8XJL3M/. 7X$'\_E=7J3-, V-=LU3,_7/<NPN&[0
M, 2#K@' +G=<?X-TQL''-!F0]X*RX1*@&T*FK-RYO "_.5+%'3,/T.*>"4Z&
M ;)A.>#T.9XG>$AU,W0,87O;<-&/@+.@4Q+11?@?AN>+%):(_R\:+X0;AN^X
M&M> )TQJN9[O,]\R?$H=/PQ,D[H;H-H';\M8E1[?7/E^6V*[4^(=':*Q! :*
MQC0FXE:P21Y]P90%V"J1;=5(O:)4QO-#,\N/_?R#9^CNVPQL1RS&PS01)%'^
MT"X!.L03-'@$HE\*K,UASM5I5U1.A]!Q46:X;D+<H1NAXU@6Z%3J@RI@@4^9
M'K"-(D#;69*8-ZLE^6,*/'Z!.UF*?R"*9+KF&P9F@$",J<DM4$HV#T%9"K$)
M+)9I=TW'68Y^-D^4E@U'0\$^J[,#.@9E!GR/@4*0WI) Q.D-B8J#A0^@_(C7
M_8T4)3 DRH PN4BXJJ8A632:Q#E-1#K)XBG)P*/+PJD:60Y( V G6L4;V-!(
M_TU@'DEH,JW:0G FTAL<APHV0B\YVWMD%KAP11['QFML^Q\RR@$AZ-9/DM*G
MS9KY?L,' ^0;KNEYEHVE()9G:KX6ADY(K7 #K;UD@;!8):" J1SHU0%DW!J.
MCNB89PI2@@8+-&$CX\:9TN4$O$W+L"N-55!DX4@)3Y)V=)<<?;@DAJGUH/]C
MCQ">F"A7:1PQ #X9? *V!MZ.&Q2A.A>^R1R#NH9EF*9O.V$HJ!: =0TM>X,L
M_$,I4F"(S* CHQ*\9:+H%NWJQC)=YL[W:JI86J\8\,H)<R$%2@I6#ZGC?]0D
M\AS0WU24-/ =4Y@!]YAC&9QZ6A!X(7B7%#0EM8PG)Q! V64-,-=(4$6@DF:\
M:^P$;S8C5]'WZR+8:99-A&PGFQ;8KAD83A PS._YH.D"L''4\'W=#\)[GFP^
M)]E,T;5VV&9D*_O>AVRU/_BT-&QH[,+&"@E6>MQ60:"8M+2YL,-%$[N\@SL<
MR-D.-\M?O-K$1#,UT1[EK,G#N3W;;HET\G1<@X?+U^L28WQ+,C &O&Z7A:.\
MN@-,MJZYB*K:>BP&6D_-C==8A5U45; A83'-LM9L\V*6<S5^#? \W._XK? K
MJ8J.KJ8C"*MVVL+3>V'7TGM^6^K\WQ.[9V6M@F)>41D#4)TWPPB^F>G7C;#>
MDD#YKER>QO$O;.!4-P*E@)JI@)#:>FCHCNO8ENY:U'1="Z+P4+=M']S_#<)O
M](2 !Z[RE'W>)3]J/4W3R065Y']H/-GHB+[M4/*[$MP^'Y3:L5".S2R[< W#
MMH/ HH$E7)/J >.^L )/N);K;))#_73^Z[-0^KM"OI?$5Q[[0LF=Y?I 5P:4
M RIK-H-8).".9GF&X6B:HS\@*$%S4.7^<0O_F\K/A4ZHPX8M,LB*Y'OQ[T)B
M^35$DJ<)QX!+D&!*F$HRCBC@YV8H5 7"0@8PR@A-"$1K<H#.S$"F-_D0X[8Q
M9@5I1K@(HZ0H#BQR59K=4O0\JW4VR0[NV7VK$E55YTB5%8ZQK)"D<C[X,X*N
ML6$==3TW!H*S<8W9>P\_SO5\JH,ZLG0G%);-@L!QK) )YEJVQCS]VSO.]=V>
MY3S^9$CIN,?S[4D[#SZB+L/HV=:KV=X=1X_5[G]1FS\J]M[,[5 G$(%C,MVP
M@#D-WW!]UZ8N,T40<BUXNMS.2Q1VW<69!+ $\IR\Z^B=6L5NARONGOJ)][8A
M6V[)6(1KU#^> ;;:DFCI(&D(ED+$@N&][215N:Y))E0O@+D\KL)W'D0J_U5<
MU$2.5&O%4US\)H*E8=E%*YW ?J"C%%\BO$,.YH@F#%/VE*F7 N!8?*D$IY)G
MQ;D5;\^[Z>8.K=-N3?O2^U:TS,\_^*YEO=WF2?F=J<<G;J^PQ6)!I<+K\"VR
M(3!LX3T75K7\IG*82WRT)7['=""Z@13T<Y>&X#/L$1K?T&DV1ZO]H:SZER:Z
M)+<VO@5#O P+Q O@FZO6.0,_+(_>#37N[JO]E6T'C*Q+"A>::46*N[F/S1R@
M8H];3 TO[K2)D[I\3@C/MKEN:)[E6,+7+5\SC%#8(:.V;W9:Q&^.?Y=R-VN4
M[D]H@E&OS^UOJ5#B?AM>**LXS<6(Z#U-!W6"2QVT!)MK0-2? \83O$:!)00I
MH:0ZFR7'Z.1'JMCF<""%.KQ9LXF5Z;3JT[P66>3=-KE_>)_5QE%] R8,-K-'
M3.>!")SWXK9'GL[!>4(6;PKNDD_JS2SDU_K5++OD-&&]72!7=16EB?5&W3;9
M0;.&%3V&]K;T(-63_O;-+E'51"J.4Z0'ZPCF#TPTK>@]-_RB:J[98383^ )@
M;$D@\AL(P94M/:KB1?C^?1H>-N*X&GRF##7%L[&Q%!E,2<OJ+C5%)L"" BLJ
M/BS.XQ4$,E.^L@I \1U2'&/&0QPB!>RD"?1I,;2)GHMZEAG\$M"H8('A.#K*
MT$]@0D&?T>+0Y$?'U@@0,D;$T@%@ 6LZ&^5I=(2^1P5] ]VJG JV%X'/ JX0
ML "?"""NJ<T!>X9-,Z!*88--4ESD2W$C-@1.*0!%3PS\F@F-$8$T2Q,0L"G6
M"D6 .%4+%-1S_SW!BLCB2E\&T<4$V:.)F& RG:&DK?3!.EQ=B5+&^;M(2SHJ
M?+OFSN:[S[:(Z(45&#A*-%(^8(:'PNDDS\!A4RO]#A2$V50Y*18Z(:TB11N@
MPJ483.*"TZ]60M?;JH26Y]K7PP8Q(O!T;\>%JXO;B=-,@0?DI@%L9B;3NEL)
M=38)_@DC*HXKRK1H?0N$33)P6B@H9IP-%X%@CD?%H?D\:O,\+J05;S57N)VI
MZA85^LHT*.)2\3ZX!'$,3$NEJFB3>.^;PG]$EK?!S9[GVC\AGQ"\6-TKB7%:
M=2['DS&=*A\G$Z.H2Y,$F#]&$T>H!$D!_0%(WBI7?*)3HMLESA5;;W7Z&?_4
M:U0'88B'75*66""?/-V^%.OJA=0J3$.T)4&1A3(=E7(WQXN]AJPTZ#NB^40J
M^6AL:U>IP][7PJZ5=0.FBT9*,^5#Y%0,'@AHOTEAVD(A,H4N5 ])!@\59P;3
MII'850^)R#%694) T%HCM=460<-,=<_)3E$[>JN@ I[_T;'TVFC-&1M8[*)<
MK%8:I+FWHJ@TJP+WA7E-RZGG+2U><TH<!;X%. I%Q \Q.=#\1].<F5#4\ABC
M%Z6ERT84+YY;A<"WV$[#KLT'X'2&#&7*,2>PB/HF-Z[88I'!&($I0ICFMH-Y
MB8%(E#]2.5@"S>08=#UP2W$&/:+3LD@:)P*XE"S@7H # P +WW('K#4$EPT[
ME*X(?!5."D3@.I3]/8F*M BT,#J.<E7\#OL "P"R ]]BH%88 X#])I6?8? ,
M"=48W'_U&9.!,@HF]:@V)Z5X_1\9QZA")@%8X8A*M*/0?R0 (7C38I*G8)<D
MOBI/*FE7=KG,R8C;**OR+T"MKT:BE]U;A3'@A:QAC)N.JJ(..-^8[8I*9JM=
MYVQ!PF>FJB;=[IR?C.DR-9K/R%@X>6*41&4!=^G.-GQ8&(,@YK4/!<Y1$,6E
MGPUSCE*)]A S4> J21!=+C(&C%#ZSV7YF=M(@RVCXJNA(HB/&*2*_28C1;&5
M>R(\A04P,ZFD6.:EPZRRCR(O]"UX=C-'K5 X34]:Z:A"M^7@>1=Z?$:_< (J
M6;UW;S5F(7!AZ7@=G !#()1NB&)8E>(YV# *HISH/9V404\)[.S6+O3$)H Q
M0+8M7P_X4$)NTJ6185I*-;[&E%/KF?_\<UL^Z35DE+R[,DHOG5,Z5P?+)_C.
MINS.U-=2WFBQXG,Q=[3,@&N.UA_,T,^JO%H3/TW[@&X@2C\9JWMQX.8(E:M)
M$O"7E../O<&/4I\KCPP=ILKTS"N:^6GF=<P,JPUEX_N@;93; )WG7Q"'OGQU
M*^G!&N:[^OAIC<3[A<3?6]1;9_Q0GY>IM$KAKZ %*6F=M:^T)5E]!G'<<E9V
MA[^I=%ASVKEUU3%/8R&[IUOE^1M*W^/_WP;!8S=6T7MO7;9HA5)](9G<7JE,
M<>3D!%RWF1%ZNN99?AA26_.%PT)/,VU?,&,[]Q#\%46#SUNRUWX/N62"MLJW
M%P#G+&TY>;]7D:;?]N*5UX+LS:L.7P"Z8Q49CC$@?*X:^I6"L4D]ST-X8-,Z
MH:?:UW/7Z%)2O%V>VH:I>ZYGBUO]+[TWS$>= X@?]_NTY643+R)O6S;::W=>
MA=G+SA3^U;'W+N$JDEYVS<L33SI*2\][D_/.[1YT*M)M%6.MNJG@AM(]F/,2
MUO++=]WP5>H&WZ]$!..]?R_M,-O[!0;'[;JABIA!=%?4952A^O(KG[_+ZW=Y
M?82\ZIKU2H3QT5LY MF0!,LNP;;5/WI6''JN$*OZC&IU[JG,D#=/EJN7PQ=K
MY&76'G\3B>R<JA]?@_@G%TD6032[+$KU+U,5BV&&["--!A, ?+/+O2WL5WUJ
MJ8E;@?/RO4^+$G^?:'W]S$\13%R=_G)V>/W[Y<D6P'RRM&OSMQR*T]_&H>9F
M%Y!VVPK?P5.;$D8GZA?.,&%:_'!!><24P:8*/HWRAID)Q)#&875PJ,J9RI[H
M\$VP2D_-2R?Y,)6P#?Z@9.LWDKBQ=5O7=:YK+. 6-P7^.@UCMN>XEFTYH;>=
MQ(V]]CUY&]@R +XP44:-R WO!3RU#E[YLP7/XRT\&K,+5W.W.]O:ZSA/YVJL
M1\HSAP?;]%6Q'JSYFRW-DC+ML;>R7P_.WD_W'KN9-9RW> 6\OOI-Y"#8T78)
M_O?F'IO>COGO'/2S/OEO$8;DN$?>4QFG-]^UR)U:Y+F)-$^@W?OEG+<%Q-$P
M$B'Y* 8T)N?J):Y2I<S R9(BI[+E<N\VO.JGO%E2>^?X$[.DN]%"*Z]QS3[O
M]_$G90_4K\SFHQ@^_#]02P,$%     @ $3QC40WEV8_#M   $)0$ !(   !A
M-3(S,3@W.#5E>#%?,2YH=&WLO6MSV]:6)OQ]JN8_8-)]>J0J6,?R)4[B,ZF2
M93G1O([MENR3SD>0!"7$(, #@)+9O_Y=U[W7QH6D;%IA)NRJSK$D$MC7=7W6
ML_YQW<SR'__G_XBB?URGR83^!?]NLB9/?_S'W_E_Y9?_Z\&#Z'4V3HLZG41-
M^4/T8E%G15K7T:]9E?*'Z/]>EN/%+"V::%RE20,?QL]=16<O?SJYF&8Y_+N.
MWEV\A7^FT;.C1T</CQZ:;Y^6\V6575TWT?'WWS^-'D2/'CYZ&+VHRF1299.K
M-'KP@ ?\=QGQ/T;E9!F-KL9E7E;_YYM_F]+_?1/5S3)/_\\WT[)H'DR3698O
M?XC^]_MLEM;1F_0VNBAG2?&_XXA^$T=U6F73YQ%]NL[^._TA.GXX;YY'3?JI
M>9#DV57Q0Y2G4_@-O>>'Z-\>TO\]_X9',\EN](WV*S03^,P_\,'!D&Y3_-,/
MT:C,)_"!LT_7V2B#21\=_^/O^($?_S&J9*+P;/>2H5_+)@T, W:M22N9WN<O
M!OWB)JFRI("1U[,DSQ^,DWDM?VE-Z=V'B].?3R[/HI.?+L[.?CE[\]Z/64;]
M'_]V_.W#Y^U?#R_D%T[@FQ_?E#?I;)16T:.8#M87C(A/PY<.J'LP.@M^MZ?W
M;<\W/[XHIR?193I>5%F3X5?.B_&1'K3M#>$;=SQIY?CYO*1#_SVIHXMT7J4U
M'-&DR6[2J)Q&S74*(X2A)GGT;E&-KQ-X?OV';];X[V74OY)?>0G?%BF(P"7L
M:_0NJ3Y^[=?AIW\KJX]QI/^"1S]\_.T?O@&ODPFL>904D^@G."]Y"GKFAR\>
M%?TF*R8I7IO'WW[FQ0L&^DL)>BZ)?DZ3O+D>)U7*YR2.DNAEFB>W\!M0)-6\
MK.#,ET5T@"?^/_[MNT>/8.#;%@DMN7Q:SN9)L72W$UYZ_/PPCN95.2]K>%Q3
M1EE=+U):YSK-<_Q-[[GGE8X.[FGD.(;+UKAID+AZ)?RG@F_?I!5(C:[TT#->
M)#.P2;(BVNXM6OQX.;Y.)PLP:D[^\??%CS+,*&F:!/\0P>A26,<#L!_R=(R2
M+E_&T3WNNRS)__P?WMJRLK5U&A(8(EAMLI[YDM:Y*)OH]S*#FR=#![D]Y\E$
MR:Q<%$T-WVC@]55SC6M<+\;7][30H#;^_=NG#V,PRO#_H^3JJDJOP "%@YT5
MXVP.IX''*!I&ET'N T[]^-GS.GI\]-VSIW^#LUYD916]*1L8T 1NPZ.'CQ_>
MZT6E5[<VYBAZ#P/@0=UF<#5'*5_6231?5/4"502<LJ2(6* M4/3 +^!C$S+&
MDQJG?YJ79)2_Q/4Y@-]-TBD8\Q-=DU&:E[>']SK;<QUOYRB.TN8V30LZ<+)9
M=!H_'%T>12^2XF/TAJ0H;/!)79?CC'Z*<:I-M:B;-+W7B;SG=W8VCJ17!-<-
MCF:5DA.%MXR&25>ISPH:EF?W.J?01&N+8+CHX[(H4!" +KO-X.Z31)Y.X8EP
MRDB/)+F;%!W?HUW4V^_-$0,QEQ834H>+.J6!%R#;0$V.8??J:%J5,_HMWK^D
M&*?]\\3O5^DD3?G#,%APEZ-_?PS"!(:9XXJ5BZ9NX,NX5DY8Z57T,NL)"Z::
M!5-A!-.CIZP&RVB>+.%M.5WU:2JV4OIICFY[K?IZS2RK=)9D!0XFF"]-*JO]
MMH*4CZ[2@LZG&C,IBB$R(^+H]CH#Z3]+\"7C?#&A,YXL*38 #\.=&\$X,88
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M#+5! GV*>693U![8'OZ 2B'1A"'.)HXX?!:C S!&\D6-N0<IOUY3$GX8!]
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M@46WW>-*AZ@X5B2AI<'51E&QK-6;D'(&&+%,"TE=VK=+WZ<@].UJ)5&2S5
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M'\S>GP,WV:^-6%@T\^V3X3;Y+0NH'=<WQ:A3DPGI'[\*Y-[>_BS@6IF6&/6
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M5-D8]R7>>9W^+*M!2$D2QE!E<"&G'QDZ%3V&ULHE]FO;JN0-P^@]>C^;(?D
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MYGT] &(%9-UD%&1&VKZD2"9)EV*6U,WO\)YZD@54W_["MI<T=FOOX\2..=?
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M'$K%Q,\,;6E]8599KGQ^K=I@Y<"BKZT91@=DW<ZLJHT#,Q8>FA*2:VUALY:
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M\$42$S-CW2)A58.]DB9!^\FS3]?9*),8S<FN(Z#WI"Y?ZX9=9^DT>IU>L2^
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M3X6G2G(R\V2I$4,G742V*.C%"Y2EB^-%3I3<2YN.>.LOD5!>\ [7"Z3=S-;
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MN1.<86WD--?3647]&6OI!LPJ[QK%L:]4V;.)3&OUUI8AY?9 O9&C9^8<>OK
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M0\HPV35Q#E%0SK2JKZ+)Y/']Y^3Q)D<6[#TW^+L)]-TTR08&WRS0DO1AAO$
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M']2"B/*,,;M*YPAG577,JMENQ*JB\EUJKD2V$;4>$,V6D'(-QJ'GG5F, \7
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M$4]:8!:*GL(,.F-EV@P4IB4GBJ4FN(#JA)!Q:& ,U"AMQ6IRT[(2J3((%PK
MV&Z)JLQI/[U)(C/6C?)6[ST5NP%SN0S!-.?6$)?A#3YVW5G2K?S!K,>3&J9]
M"W0J1? P*'V8,ICA$?=B6B'M9LB=GL(XO4<O-BABZ(X1!A3>-[/V3'AG6#=K
M)9&&)[LZWJM"AG9GS(9<WKH\E'XA&0ED/Y^.'+)?KBFKR&6OE"7\I+5(:CJ[
MPV7S2#E1[K!5$9F!R"1\8!>B]OG;2V]9C<O&P U!4FCA&WOW;:7P>#2YK%ZO
MO=\%^!8:X-OL GS.G &^SHVR/-R?F,7!IT.RB_LR0<1989#9NFAH3^)\C-#0
MQ%[CFZXC:B2=2XX&-<BI)@[/2]6NG<RG]!X9J6R9/&J?.@;*&J?^,O7A=&ZH
ME6$F903G;./C*A/UE;!0#V@6%E-67Y<:KRP%.I_$L]S?:1WVP!B &RA=:+4[
M*KULMT)9D6:0EPLK71;]&=GP7O7+$FW4,/B%!26RPGSTFE$[&/3(N4YODTCX
M<-W!37GWWNGM;?=6OJZNRR%L_B+'P<GE9MQ?P>P,TQCN,DR<FA'I]?KB.:'U
M'$]F(^"B(LT0Y#IFF/[A^O'ZI9K^YL[F^MXF2 W.+JV/CQUMGFWT[7?K6S2V
M;&30X%"5$SF^.GFV>6SM;:[C)JA3M%C:;)2FYO,(DK)F8YY,S\4]VL3]P3GV
M4"0982;LSTTM7-3$IROC-CG*/!.D.RJA$5[F#R$5PH*8R$MNA62V5!3)=11U
M O$V*F-1E6?'K8F:KK'!J7-R(HG]0QH$:\?PS*_.'[@[5P5P=]CED/#W&3XJ
MP73;# %H"L$'6D8WP!D;IS$GB_^M77N;H^9'J.Y/3M+Z7^V]1_4Y=XZ)3_RK
MLUH68K5L=5;+PV3_HEF))U(<RG+:*&_@ELXD+3,[&.X2TE5.*538M"/DSW =
MAI?(>I5JU ]9MX&\E8\]7U64J&1GTK,?E7AG;==3]^:?&'@KLC*>T-IR=U:6
MI@A;= (/XQ@7"NO^QT\;/]'?8VP-+_YF\J1?\1;\Q_?"C:V]X887^(-M?^!Y
MN[O;F[O;&_O;>[O[[\+@IP5=YBHMFU1OWBW]&RXI^\W\&U\)Y'S$ W8JW]>W
MO&'#U-N_%$'#DV&.L'7)/W[:_,G)TGO^O??3;Y_/3T_.^LZGH_[I]:?#_N61
MZYR<':ZW/,6>W^;.>G6)CYLBO&#OQDOO3N7)S_7@S6>;\NL?A2-NHA*[R.:?
M[7Q:1CN8_*KEP7P;B$L0\LUX)J8T1H&3W0Q6-EP'_[\*P_R2_[+8+&'1U^=T
MG5K[*.$^T\$_V]8OXZT\\T;A4XYXP>Z.IYS;:U_89SPELIN6Z)A:.F4MPWDI
M%><7TG'F5F7G#B%;FIEI.?QFGE?=L'BMMQ?E_IO^<\[B)FDK-I$IVV]1 1_U
MZY8P.ENDWUIK]/^2I-@^B^>VB'\TNW%>(^A9*ME,@]'J<B%*P'3O05V;/Q4&
MS5/A! *_@B]C0)K@IT7N]JSFX&+\28LP(/F%.R^+/-S[?.3%\9KOC9$ &WM;
MSCXQ<2_P#QAL;R'@-@PC8+4!BHH\C(>+S1.S&"8Q#R(1=O%6>BBGSS[V])JK
MIQ+0@M4!M!)^H"!5RQUY=/RP.YG%^(T(OA%-R<]> ??GWCDL,^ =!I+C:QT#
M6UE+=!#.<]R+ZK:_ZI8+DVF)]OR%SR+Q;@A_3Y2LSAG\FJ*_SPM<\&RZ?:?1
M+XM&3P7JBU%+J^7XAY^./GPY/4*@XR>IV8^+>&SL;@RWW^UNA_M[PVU_RQ_T
MAL-@V!OL[ ?[F\/-P:(B'G5->K88B$%=-:]50)WR;A(D+B1J-5?0*HO(]V(Y
M(+\]J[=6SN3=7MU[,X?%M_9N=WUG7#49Y(M/CAY.59FEIEWU)#5LF0KS]!:\
M?3W</4G"\TQDLW4BP,UF=[G/=G!-%_N__N_6WOM_EVDQXQ7N*_3_"PG_UNC8
M>\XIU!"I7WH&@U#18O!(4DS2^\P;H^C ?QM)LW[GGIM8*][7)W AHM['\I9%
MFTW3+#P:J%$]G%7#)!;U,G[8[N=;_-F8C?0<,NNIPN@QK&=Q8[:-T,"\Y:#[
MTQG+4_6.WNZFN[.QX8+*M@Q<_JVP[SE4PT6[";(RRHN.UW<_.U[?\?JY>/W^
MMKNYT['Z-\/J#[S,C[&;R*$W1H]CQ^B[GQVC[QC]@XQ^=Z]C]&^)T7\(RR+W
M;T/G  O+M&K?,?SN9\?P.X;?,?SOC.'_OGZQ[GQ.LQLO,=G]Z>EAQ^V[GQVW
M[[A]Q^V_'V[_^<OQ1Y/-]T?PAN]UZGWWLV/X'</O&/[WQO#_P*1-YQ@&2JU
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M)PT"C@QV(L>A;K(PU*@"ZS!3#,W"RN.):^)@W-^FL(7Y+6T=/<3T<9*O5K_
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MF],FL^PM@+];EAN\AKTK](#HIG"J,QN68#RJ*3GC]#Y$%3_0O R,B-N4T(*
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MGYDPH=+&<AXA;NU6R_:\$<<PRVH&X4+.%JYV;\K7:4CH"Z'%9^Z/.1M%55S
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M))>!A;?Z"MF=.-VP*_[%XU537'Y1]^QO4$L#!!0    ( !$\8U'_RV7S'P8
M !1"   4    ;6]H+3(P,C Q,3 R7W!R92YX;6S57%UOHS@4?5]I_P.;>2:$
M9'=F4[4SRO9+U63:J,UJ/UY6#CB)M8 CXS3IOU^;V-G8&' F;654J:7<X^M[
M? X!+K3G7[9IXCU#DB.<773";J_CP2S",<H6%YUU[H,\0JCSY?.//YS_Y/NW
M,(,$4!A[LQ?O^NIV]#A'"8/FWN3Q@6U"[U.WQ[^\WP@&,4'Q OH^'\Q0_Y[Q
M;S.00X]-FN5GVQQ==):4KLZ"8+/9=#>#+B:+H-_KA<&?W\9/T1*FP$=93D$6
MP8['\&=YL7.,(T"+B@^&;V<DD0D&P7ZN2@3_S9<PG^_RP[X_"+O;/.Z($GG8
M8A()WY;P@E,X' Z#(KJ'LD2H)O6>-EL]S]NM'\$)?(1SC__\_?&N<O0PX(@@
M@W0,9C!A4Q;#Z<L*7G1RE*X2*/<M"9R;\R2$[-/PU1GRU0D_\M7Y\'_FX)3R
M%MQ*4TQ!\CIU%OG*M9:F.;WH^]=:VKJ2[U]SE=DA#M]AE0^F.;WH"20(Q]=9
M_/:%ZU.]5O%/%)!WL$IYLM,)O'W51Y2:8A8&2P@2NHP @=T(I[LIKG"T3F%&
M1QF3CR+Z<I?-,4F+\T-S]2E>LN+ZO3#L]8O2ZM,=EKHB,&? (C)F.Y2YX);"
M+(:QG(V7>BJ98FXY>X(C9<*$GQ(Q*6N3LPD+87(8=1?X.8@A8F*'0[[A\PV_
M%XK3W@>VZY]+S*X'1K.<$A!1F2_A4EUTC#%6)R>GQ8)W*E<NV93EU:HUA42Q
M:DBM]5#8$5'K!B22F=BFHFKY'"X0P8IIG%$_6J)D;X@YP6G5>N+:T@_+._.4
M#![%GCH2DQB2BTZ/7]BQ@7-(B#CN:NHNBDX.#\ZWEW'$:HYYW3<)6&@Z&F-B
M-;28>TK6%=\@I394:!DZKZ6TX/ZD>L4^[2N.32-&.T@UC'L:VY"Q/&RU%$+S
MOO.:[TY7CW"!.*>,WH-4E[P.(A;)#'%/< LJ#7J;,PBY!RV1^RZ+,%EA4I!D
M5Y\47N)U1LG+)8[-ZEN-4,S0,,)5;QQ#U,HJ#0F%<WYNB7-N4 +OU^D,$J--
MRF'%$X=A5PU02<%*[</10MI?6B+M%&SO8D80S=&N2U>C<P-6$;T2ZZH#[,A9
MV:$RE?#&QY9X8Q3'C&XN?K"[9A@:?5&#4SQAQ+GJAV925EXPIA$^^-1:'_0M
M?="W]$&_33[027VG#_I['_S:6A\,+'TPL/3!H$T^T$E]IP\&>Q\,V^6#2[;Y
M0*9XD]6YH(PR>> 0Y;@#*@D=H_]A$MDI<K_MIU H[FH>R(3@9[1[XEOI@0JH
MR0@EJ.-NJ*=VC"5*F:0OW&\AJM;>W>C6?B:H$.,'@H0XKK^9RE$?!3*#U+LM
M[4-1_P3G%"1_HU5E&ZD.:-)> SKN@#I:Q_A RR/=X'YWD9_+1@0"@_ZFD'P
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MFW<>E)9JS';P_\VPB_!O_'\9?/X/4$L! A0#%     @ $3QC42Y!6T4)%@
MY7L   T              ( !     &$U,C,Q.#<X-2YH=&U02P$"% ,4
M"  1/&-1#>79C\.T   0E 0 $@              @ $T%@  834R,S$X-S@U
M97@Q7S$N:'1M4$L! A0#%     @ $3QC44VR[@; "@  %QP  !,
M     ( !)\L  &$U,C,Q.#<X-65X.3E?,2YH=&U02P$"% ,4    "  1/&-1
MFUUX[W,#  "9$   $               @ $8U@  ;6]H+3(P,C Q,3 R+GAS
M9%!+ 0(4 Q0    ( !$\8U$1<#/E[P@  /%<   4              "  ;G9
M  !M;V@M,C R,#$Q,#)?;&%B+GAM;%!+ 0(4 Q0    ( !$\8U'_RV7S'P8
M !1"   4              "  =KB  !M;V@M,C R,#$Q,#)?<')E+GAM;%!+
4!08     !@ & 'X!   KZ0     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
